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Abstract
Comprehensive Analysis of γ-Hydroxybutyrate and γ-Hydroxyvalerate
by Jennifer Wiseman Mercer

γ-Hydroxybutyrate (GHB) and γ-hydroxyvalerate (GHV) are suspected agents of drug
facilitated sexual assault. Research is needed to improve detection methods for both drugs for a
range of instrumentation commonly available to forensic chemists. GHB evidence may be
introduced to the laboratory in the form of a powder, solution, beverage, or biological sample;
thus a key theme of this research is overcoming matrix effects for comprehensive analyses. As
GHV is not commercially available, it was synthesized for analysis via base hydrolysis of γvalerolactone (GVL). The results of the synthesis were confirmed using infrared (IR)
spectroscopy and proton nuclear magnetic resonance (H1NMR) spectrometry. As no
presumptive test is currently available to forensic laboratories for GHB, methods were developed
to screen for GHB and GHV using microcrystal testing and ion mobility spectrometry (IMS).
The microcrystal test investigated was found to be sensitive (to 0.01% w/v) and selective (based
on crystal shape and angle measurement) for both GHB and GHV in solid forms, solutions, or
beverages. Further, X-ray diffraction (XRD) was used to confirm the identity and placement of
GHB and GHV in the crystals formed. Application of XRD to drug crystal analysis is novel and
may reinvigorate this collection of fast and simple screening techniques. The second screening
technique, IMS, was found to be sensitive (positive alarm response at 3ppm) and selective for
GHB analogs and GHV analogs in solutions and toxicological samples. The published IMS data
was later chosen as a Selected Article on the Analysis of Drugs of Abuse in Biological
Specimens (July – December 2006) by the United Nations Office on Drugs and Crime. To

complement the investigated screening technique, a sensitive confirmatory technique, gas
chromatography-mass spectrometry, was validated (limit of detection 1pg on column, 100ppm in
solution) for GHB and GHV in beverages. Lastly, the metabolism of GHB in the presence of
alcohol was studied to improve understanding of the effects of coadministration. A literature
search revealed that coadministration results in effects that are greater than additive; however,
the mechanics of this interaction continue to elude forensic toxicologists. In this study, the basic
cytosolic metabolism of GHB was studied to look for trends in GHB elimination in the presence
of ethanol. Although no interference constant was able to calculated, the presence of alcohol
was shown to decrease production of NADPH, a product of GHB metabolism. A decrease in
product further promotes the theory that ethanol inhibits at least part of the metabolism of GHB.
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Chapter 1: Introduction
1.1.0: γ-Hydroxybutyrate
γ-Hydroxybutyrate (GHB, Table 1.1) has become widely recognized in the forensic and
emergency medical communities as a consequence of its illicit use, including reported steroidal
effects, recreational use, and as an agent of drug facilitated sexual assault (DFSA) [1]. GHB or
4-hydroxybutanoic acid (formula C4H8O3) is a short chain organic acid with a pKA of 4.72; it is
also a central nervous system depressant inducing effects of euphoria, sedation, catalepsy, and
ataxia [2-3]. Available in salt form as a white powder that is readily soluble in water, GHB may
be administered in beverages for recreational usage or DFSA [1].
1.1.1: Analogs
In addition to GHB its analogs, γ-butyrolactone (GBL shown in Table 1.1) and 1,4butanediol (BD), have become well known for their similar illicit uses, including DFSA [1]. A
similar compound, γ-hydroxyvalerate (GHV shown in Table 1.1) is the 4-methyl-substituted
form of GHB and represents an emerging drug threat as does its lactone and diol analogs. GHV
and GHB have shown similar effects: namely sedation, catalepsy and ataxia. However, GHV
requires higher dosages; increasing the threat of toxicity and lethality [4-5].
GHV has been commercially available as a dietary supplement and replacement for
GHB, although the internet sites that advertise it, now list it as “sold out”. As GHB was listed as
a Schedule I drug in 2000, drug abusers may switch to the uncontrolled substitute, GHV [5] .
Given the increased dosage level, the inherent toxicity of GHV is a significant concern, and its
detection and characterization will become an important issue in forensic toxicology and solid
dose analysis.
1

Table 1.1: GHB and analogs
GHB

GBL

Structure

GHV
O

O

O

CAS

96-48-0

t½

591-81-1 GHB
502-85-2 NaGHB
104.10 GHB
126.10 NaGHB
0.3-1.0 hours

Solubility*

50 g/L

LD50**
Density

FW

O
O

OH

OH

GABA

O
OH

O

OH

GVL

108-29-2

56-12-2

100.12

103.12

N/A

N/A

103.1 g/L

9690 mg/kg

1540 mg/kg

8800 mg/kg

12680 mg/kg

N/A

1.129 g/cm3

1.052 g/cm3

N/A

86.09

13532-37-1 GHV
7132-53-8 GHV(-1 ion)
140.11

OH
NH2

N/A

*In water.
**In rats.
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1.1.2: Interconversion of Analytes
The similarities between GHB and GHV include use by mixing with water or alcoholic
beverages, use in DFSA, and synthesis of the acid from analogs. γ-valerolactone (GVL, shown
in Table 1.1) may be hydrolyzed to form GHV using a base, such as sodium hydroxide, as a
catalyst (reaction shown in Figure 1.1); just as γ-butyrolactone (GBL) may be hydrolyzed to
form GHB [4]. Methods for hydrolysis of lactone solutions are available online and some
lactone solutions have been sold as “kits” including some type of base.
In solution, the lactone forms, GBL and GVL, have been shown to hydrolyze to the free
acid forms, GHB and GHV, as a function of solution pH, time, and temperature. Ciolino et al.
showed that hydrolysis occurs under acidic, basic, and neutral conditions varying according to
pH. In strongly basic solutions (pH 12.0) 100% conversion of 0.5% w/w GBL to GHB occurred
in 15 minutes at ambient temperatures; making base hydrolysis a practical approach for synthesis
of GHB from GBL. In strongly acidic conditions (pH 2.0) an equilibrium of 2:1 GBL:GHB was
reached in nine days from the starting concentration of 0.5% w/w GBL [6]. Interconversion of
analytes has important legal, forensic, and toxicological implications.
Several studies use intramolecular esterification to convert all free acid into lactone form
for simplicity in analysis. For example, LeBeau et al. found that addition of 0.15 µL of
concentrated sulfuric acid was sufficient to extract 96.5% of GHB to GBL in 1mL aliquots of
test specimen over a concentration range of 6ppm to 700ppm within 5 minutes with no additional
heating required. Conversion to the lactone enabled extraction by methylene chloride and
detection of GBL using GC-FID and GC-MS. This method has been successfully used on
casework by the Federal Bureau of Investigation [7].

3

Figure 1.1: Hydrolysis of GVL with NaOH to form GHV
O
OHO

O OH
O

O
-O
OH
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1.1.3: Significance
A drug facilitated assault involves the surreptitious use of a substance to incapacitate a
victim. These assaults may result in theft and/or sexual assault of a victim [8]. Drug facilitated
sexual assaults (DFSA) are recognized within the legal community to be more difficult to
prosecute than other types of assault for several reasons. Foremost, substances administered in a
DFSA are occasionally chosen for their ability to cause anterograde amnesia (specifically GHB
and a benzodiazepine known as flunitrazepam feature this effect). Flunitrazepam is 6-(2fluorophenyl)-2-methyl-9-nitro-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one and is
also marketed as a treatment for chronic insomnia under the trade name Rohypnol®. In addition
to memory loss of the sexual event, victims of DFSA may fail to realize an assault has taken
place or may be incapable of summoning help in sufficient time to allow for forensic and
toxicological testing given the short half life of possible DFSA agents [9]. For example, GHB
has a half-life of 0.3-1 hour and is generally undetectable 8-12 hours after administration [2]; this
is also partly due to the presence of endogenous GHB in the body at concentrations of 10ppm
and below [7,10-11]. Furthermore, victims with an unclear memory of the assault may be
hesitant to appear in court as an unconvincing witness. A final contributor to the difficulty in
prosecuting DFSAs is a general lack of physical injuries; a side effect of the euphoric, sedative,
and cataleptic effects of the substances used [9].
A recent Canadian case sought to minimize the effects of a negative drug screen on
behalf of an alleged victim of sexual assault. Such negative screens often result from a victim’s
inability to remember the assault and/or to seek medical and forensic help immediately following
an attack. The prosecution sought permission to introduce an expert witness to testify to the
following: (1) negative screening results are not conclusive proof that no drugs were present at
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the time of the alleged assault, (2) approximately 10% of drug agents believed to be used in
DFSA are undetectable by forensic screening, and (3) some otherwise detectable drugs are
rapidly eliminated by the body and may not remain at the time of screening. Although the
defense argued that the expert testimony was prejudicial to the defendant, the judge ruled that to
include a negative test without expert testimony would mislead a jury who might lack the social
framework necessary to understand it. Social framework evidence has been defined as evidence
which provides jurors with information beyond the common knowledge of a layperson which
assists those jurors in evaluating forensic evidence [9]. Although social framework evidence is
allowable in court, it would seem that improving analytical techniques for drug detection and
providing jurors and the scientific community with more information about the metabolism of
agents of DFSA would be a less prejudicial solution to the problem of how to prosecute these
types of assaults.
To evaluate the prevalence of drug agents used in DFSA, a survey of urinalysis samples
from a population of 3303 alleged DFSA cases submitted by U.S. authorities between June 1996
and February 2000 were studied and the results incorporated into a database. Submissions were
made from rape crisis centers, law enforcement agencies, and hospital emergency rooms on a
voluntary basis for any client complaining of DFSA. This study contained the largest number of
cases to date according to a literature review. The database revealed that of 3303 submitted
sample, 2026 tested positive for one or more drugs (including alcohol). The most common
substance identified was alcohol (1358 samples, 67.0% of positive samples, 41.1% of all
samples). GHB was identified in 100 samples (4.9% of positive samples, 3.0% of all samples).
Given that GHB is no longer detectable 8-12 after administration, the authors noted that GHB
may be underrepresented in all analyzed samples which were sorted into time frames of “tested
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within 24 hours of assault” and “tested within 72 hours of assault.” The authors did note
multiple instances of GHB appearance with polydrug use (See Table 1.2). Although the
urinalysis results indicated that no cases contained only GHB and alcohol, it should be noted that
16 cases contained GHB, alcohol, and some other drug [12]. The other drugs detected in these
samples include cannabis, benzodiazepines, cocaine, and amphetamines. Cannabinoids have a
long half life (Δ9-tetrahydrocannabinol has been detected in urine up to 12 days following use)
and may be detected in the body long after use due to their hydrophobic nature [2]. Therefore
the presence of a cannabinoid does not indicate that GHB, alcohol, and the cannabinoid were all
consumed during a single dose event. Benzodiazepines have been investigated as an agent of
DFSA or could result from common prescription use. Cocaine and amphetamines are
psychostimulants and therefore less likely candidates for agents of DFSA. The presence of these
stimulants could reflect voluntary drug use by the victim. In fact this study could have benefited
from a survey of victims to anonymously indicate any drugs voluntarily used prior to the DFSA
[8]. A recent review of relevant publications found reports of GHB use in DFSA to range from 0
cases to 4.3% of cases. Only one of the published studies accounted for voluntary use and found
covert drugging in 2% of reported DFSA (18 of 1014 studies) [8]. Upon completion of their
literature review of DFSA databases, Beynon et al. called for surveys accounting for voluntary
use as a new standard for publications surveying reported DFSA results to improve data
available for review.
In addition to the previously described survey, the Drug Abuse Warning Network
(DAWN) records instances of ER mentions of drugs of abuse. A mention may include: the
results of laboratory testing, a clinical assessment or diagnosis, or any reports from an incoming
patient, their friends, or their families. In fact, DAWN no longer records data as a “mention”
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because there was an assumption that only self reported data was included in their reports.
Figure 1.2 shows a graph of the prevalence of GHB mentions in emergency rooms over a 12 year
period [13]. Given that a thousand cases have been reported every year in the past three years
indicates that GHB is still of concern for its adverse effects which may be suffered by both
abusers and victims of DFSA.
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Table 1.2: A summary of DFSA urinalysis involving GHB
Detected GHB plus:

Positive
Cases
No other drug
61
Alcohol
0
Alcohol + Cannabis
2
Alcohol + Cocaine
5
Alcohol + Benzodiazepines
2
Alcohol + Cannabis + Cocaine
1
Alcohol + Cannabis + Amphetamines
3
Alcohol + Cannabis + Benzodiazepines
1
Alcohol + Cocaine + Benzodiazepines
1
Alcohol + Cannabis + Benzodiazepines + Amphetamines + Other drugs
1
Cannabis
6
Amphetamines
1
Benzodiazepines
4
Cannabis + Amphetamines
1
Cannabis + Benzodiazepines
2
Cocaine + Benzodiazepines
1
Benzodiazepines + Amphetamines
1
Cannabis + Benzodiazepines + Amphetamines
1
Cannabis + Benzodiazepines + Opiates
1
Cannabis + Cocaine + Amphetamines
1
Cannabis + Cocaine + Benzodiazepines
1
Cannabis + Benzodiazepines + Amphetamines + Opiates
1
Cannabis + Cocaine + Benzodiazepines + Barbiturates
1
Cannabis + Cocaine + Amphetamines + Opiates
1
Total GHB Positive Cases
100

Reproduced with permission from reference [12].
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Figure 1.2: Emergency Department mentions* of GHB as recorded by DAWN

Total Mentions of GHB

ER Mentions of GHB
6000
5000
4000
3000
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1000
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Year
*A mention may include: the results of laboratory testing, a clinical assessment or diagnosis, or
any reports from an incoming patient, their friends, or their families. In addition, DAWN
changed their measurement methods for the 2003 survey and then again for the 2004-2006
survey; which could influence some of the features seen. This figure represents a summary of
data presented in reference [13].
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1.2.0: An Overview of Forensic Chemistry
Forensic chemistry is the application of traditional chemistry and instrumental methods to
samples of legal interest. Forensic laboratories oversee chemical and instrumental testing of a
variety of materials including powders, plants, solutions, and biological fluids. The West
Virginia State Police dedicate three laboratories to forensic chemistry: Toxicology (the analysis
of breath, blood, and urine for alcohol and drugs of interest), Controlled Substances (the analysis
of powders, plants, and solutions for drugs of interest), and Trace Analysis (the analysis of
glasses, fibers, paints, gunshot residues, and arson residues). This research focuses on
improvements in controlled substances and toxicology analyses. A common procedure for
testing of seized evidence is a screening of all incoming samples for broad classes of drugs,
sometimes influenced by information from the submitting officers, followed by confirmatory
testing of the sample.
The West Virginia State Police Toxicology Laboratory uses an enzyme multiplied
immunoassay technique (EMIT) to screen for ten classes of drugs (amphetamines, barbiturates,
benzodiazepines, marijuana, cocaine, methadone, methaqualone, opiates, phencyclidine, and
propoxyphene). The Controlled Substances Laboratory relies on color testing for screening of
seized samples with analyses influenced by probable cause (based on the submitting officers
report). Positive screens are further subjected to gas chromatography-mass spectrometry
analysis. Any drugs detected are quantitated according to previously performed calibration
curves. Not all drugs are detected by an EMIT or a color test; for example, the failure of these
techniques to detect γ-hydroxybutyrate (GHB) will be discussed in a later section. Therefore, to
test for GHB, the submitting officer would have to indicate his suspicion that the drug might be
found. As of August 2002, the lab had never detected GHB in any toxicological samples
11

submitted. This could indicate that GHB is rarely found in the tested population, it could be a
product of the fast metabolism of GHB, or it could indicate that the current screening and
confirmatory methods are insufficient to reliably detect GHB.
The research described here sought to test the sufficiency of reported methods to detect
GHB and to test these methods for their suitability to detect and distinguish GHB and γvalerolactone (GHV) which was recently reported as an agent of DFSA. The techniques
addressed in this research cover a comprehensive analysis of GHB from screening techniques to
confirmatory techniques and a discussion of metabolism. Techniques addressed in this research
span the entire matrix of GHB evidence submission, including powders, solutions, beverages,
and biological samples. In addition, later work focused on the relationship between ethanol and
GHB, as they may be coadministered in DFSA, to determine whether ethanol inhibits the
metabolism of GHB. Inhibition of the metabolism of GHB is a key point of contention for
forensic toxicologists who note greater than additive effects of coadministration without
addressing the metabolic cause of said observed effects.

1.3.0: Instrumentation
When addressing comprehensive analysis of GHB evidence, it is important to understand
the instruments and standards available to the average forensic scientist who may be examining
GHB related evidence. In the field of forensic science, several technical and scientific groups
exist to review and suggest standards for scientific work. For example, The International
Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) is sponsored by both
the Drug Enforcement Administration and the National Institute of Standards and Technology
and offers the following recommendations for the analysis of seized drugs. Analytical
techniques are sorted into three categories. Category A techniques include infrared
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spectroscopy, mass spectrometry, nuclear magnetic resonance spectroscopy, raman spectroscopy,
and x-ray diffractometry. When a validated Category A technique is used; it must be
accompanied by at least one other technique from any category. Category B techniques include
capillary electrophoresis, gas chromatography, ion mobility spectrometry, liquid
chromatography, microcrystalline tests, pharmaceutical identifiers, thin layer chromatography,
and macro/microscopic examination (cannabis only). A hyphenated technique, such as gas
chromatography-mass spectrometry, is considered a suitable combination of Categories A and B
only if information from both methods is used (such as GC-MS when retention time and mass
spectrum are used). Category C techniques include color tests, fluorescence spectroscopy,
immunoassay, melting point, and ultraviolet spectroscopy. Category C techniques are
presumptive and are generally used to screen for certain drugs or drugs classes and are followed
by confirmatory testing [14]. For this research, the following techniques were selected for
analysis of GHB evidence based on availability of instruments and resources in our research
laboratory, the West Virginia State Police Forensic Laboratory, and the West Virginia Medical
Examiner’s Office: crystal testing, ion mobility spectrometry, and gas chromatography-mass
spectrometry.
1.3.1: Infrared Spectroscopy
Before work could begin on GHB evidence analysis, the unavailability of GHV standards
had to be addressed. As previously stated, GHV free acid may be produced by base hydrolysis
of the lactone, GVL (standard available for purchase through Sigma Aldrich). To ensure
production of GHV and purity of product, IR spectroscopy and H1NMR spectroscopy were
performed on the soapy white powder that was produced.
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Optical spectroscopy involves the following processes: absorption, fluorescence,
phosphorescence, scattering, emission, and chemiluminescence. A spectroscopic instrument
requires a stable radiant energy source, a sample container or chamber, an optical agent that
restricts available wavelengths, a detector which converts photons to electrons, and a processor
which interprets current as a displayable signal.
In this research, infrared spectroscopy was used which involves the absorption of light in
the 4000 to 400 cm-1 frequency range. Infrared light is absorbed by molecular bonds in the form
of vibrations, if the vibration is sufficient to cause the molecule to undergo a change in dipole
moment. As infrared light is absorbed, the loss of certain absorbed wavelengths is seen as
valleys or downward peaks in the resulting spectra. These peaks can be related to functional
groups as certain bonds absorb specific frequencies of IR light.
IR analysis is useful for solutions (which may be sandwiched between IR inactive KBr
plates) and solids (which may be directly analyzed, ground and mixed with KBr to create pellets,
or dissolved in chloroform and suspended between KBr plates). This research relied on
microspectrophotometry interfaced with a traditional IR instrument. The use of a
microspectrophotometer allowed light to be focused on small KBr pellets containing the analyte
of interest.
1.3.2: Nuclear Magnetic Resonance Spectroscopy
The theory behind NMR relies on the assumption that certain nuclei (1H, 13C, 19F, and
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P) rotate around an axis and have the property of spin. Spin requires angular momentum which

is quantized as an integer or half-integral multiple of h/2π (h is Planck’s constant). The specific
nuclei of interest in this study (1H) features a quantum number of ½ with spin states of +½ and –
½. If the nucleus is charged, spinning of the charge creates a magnetic field. When that
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magnetic field is brought into an external magnetic field, its magnetic moment becomes oriented
along the field in one of two directions depending on quantum state. Absorption or emission of
electromagnetic radiation can cause a transition between energy states. In FT-NMR, nuclei are
briefly subjected to intense radio frequency (RF) radiation, exciting nuclei to a higher energy
state. As the nuclei relax, an RF signal is released and detected. In this way, protons are
detected in H1NMR.
As the magnetic moment of a nucleus interacts with magnetic moments of adjacent
nuclei, the magnetic field created affects the distribution of electrons in the bonds. Changes in
electron distribution manifest as splitting of the energy levels and cause multiple transitions.
Thus, an H1NMR offers information about the spatial relationship of protons in a molecule. This
is known as spin-spin splitting and the following relationships are observed: no nearby protons
produce a single peak (singlet), one proton on the adjacent molecule (-CH-) splits the resonance
into a doublet of peaks, two protons on the adjacent molecule (-CH2-) splits the band into a
triplet of peaks with a 1:2:1 ratio, and three protons on the adjacent molecule splits the band into
a quadruplet of peaks with a 1:3:3:1 ratio.
In addition to coupling effects, the various components of a molecule can offer shielding
to bond electrons. Shielding is related to electron density of surrounding bonds and is expected
to decrease with increased electronegativity of adjacent groups. This shielding manifests as
chemical shift of the incoming signal of bound protons. In this way, H1NMR offers information
about the spatial relationship of protons to certain functional groups within a molecule.
1.3.3: Crystal Testing and X-Ray Diffractometry
Microcrystal and color tests have been used for the analysis of drug and other analytes
since the 1800s. Crystals that form in the presence of an analyte and reagent are identified based
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on their morphology (size and shape) and behavior (speed and location of formation) when
observed using polarized light microscopy. While it is recognized that crystal tests are of value
[15-18] , their place in the forensic analytical scheme is no longer central. This can be attributed
to the lack of analysts trained in microcrystal recognition, the subjective nature of such
identifications, and the availability of screening methods that may be faster (instrumental
techniques) or broader in scope (EMIT and color testing). However, there are types of evidence
not amenable either to EMIT or the color-based presumptive tests used to screen evidentiary
drug samples. In such cases, a viable crystal test would be useful for screening purposes,
particularly if the reagents are readily available and the crystal is distinctive and can be
unambiguously associated through known structure and quantitative measurements to a specific
drug or analyte. For example, GHB and its analogs are not included in the drug classes screened
for using EMIT and do not lend themselves to distinctive color testing. In fact, the only color
tests suitable for identification of GHB are weak acid/base indicators that respond to the weak
acid characteristic of the molecule. These analyses are nonspecific for GHB and are rendered
useless in complex and colored matrices (such as a beverage) [2].
Currently microcrystal and color tests are considered screening techniques because the
specific chemical identity of the crystals is not readily known. To this end, x-ray diffractometry
(XRD) can provide confirmation of the presence of specific compounds incorporated into
crystalline matrices. X-rays are electromagnetic radiation with a wavelength of 10-5Å to 100Å,
traditional instrumentation only uses 0.1Å to 25Å. This wavelength puts x-rays on the same
scale as the distance between atoms in a solid or crystalline matrix. As long as the matrix has a
regular spatial distribution, scattered x-ray diffraction accumulates as the beam penetrates
through the atomic layers. The Bragg equation (Equation 1) sets the conditions for constructive
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interference when radiation strikes the crystal at angle θ, n is an integer, λ is the wavelength, and
d is interplanar distance.
nλ = 2d (sin θ )

Equation 1

Atomic species are identified based on the position of the resulting lines and their relative
intensities. Distance (d) is determined based on the known wavelength and diffraction angle.
Crystals are identified empirically (based on the unit cell) and may be classified into one of six
systems, based on three dimensional repetitions of atoms in the lattice. For example, Cubic
crystals feature equal spacing of atoms along three perpendicular axes. Tetragonal crystals
feature equal spacing of atoms along two perpendicular axes normal to a plane of different
spacing. Hexagonal crystals feature equal spacing of atoms along three axes that are 120° apart.
Orthorhombic crystals feature unequal spacing of atoms along three perpendicular axes.
Monoclinic crystals feature unequal spacing along two oblique axes. Triclinic crystals feature
unequal spacing of atoms along three mutually oblique axes [17].
When comparing an unknown crystal to a known crystal sample, an exact diffraction
match can confirm identity. XRD analysis of common crystals produced in microcrystalline
screening could restore crystal testing to a place of prominence in forensic drug testing by
confirming that only one analyte can form the crystals observed; making crystal testing a fast and
efficient confirmatory technique. This research identified a microcrystal test suitable for the
identification of GHB and GHV. The crystals were further subjected to XRD analysis to confirm
identity and set a precedent for future microcrystal studies. Surprisingly, this research was the
first published application of XRD to forensic crystal analysis. Since publication of this work
and presentation at the annual American Academy of Forensic Sciences meeting, other groups
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have performed and presented similar findings aligning crystal results with XRD analysis but no
other publications have been found as of the preparation of this dissertation.
1.3.4: Ion Mobility Spectrometry
A second screening technique was tested for effectiveness on GHB and GHV analysis.
Ion mobility spectrometry has been used for nearly 30 years as a screening device for the
detection of drugs and explosives and has seen a recent boom in popularity given the
instrument’s suitability for portable work in airports analyses for explosives [19]. The
advantages of IMS include atmospheric pressure operation, minimal or no sample preparation,
fast analysis time, excellent sensitivity, and simple operation. The disadvantages are lack of
specificity and small linear response range. However, IMS is ideally suited for semi-quantitative
screening purposes and has been employed by the pharmaceutical industry for this purpose [2026].
In a mobility spectrometer (Figure 1.3), ions are created in the ionization region at
atmospheric pressure using a soft ionization technique (beta particles from 63Ni). Generally a
370 MBq 63Ni source is used [27]. When 63Ni nuclei decay, beta particles are released. In the
presence of air, beta particles form reactant particles as seen in Equation 2.
Equation 2
Water, which may be present in the N2 gas, gives rise to several ion molecule clusters, including
(H2O)O2- as seen in Equation 3.
Equation 3
Product ions may be formed through associative electron capture as seen in Equation 4.

Equation 4
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Ion molecule clusters form and enter into the drift region and travel toward the detector
against an opposing drift gas flow. The drift region features a uniform electric field gradient of
1-500V/cm. Separation of the clusters is based on mass, charge, and collisional cross section
(size and shape of ions) [27]. The method is reminiscent of electrophoresis and indeed one of the
earliest descriptive terms for the procedure was gas phase electrophoresis.
A mobility spectrum consists of a plot of current intensity at the detector as a function of
drift time. Typical drift times are in the range of 2-20 milliseconds. The drift time depends on
velocity and the electrical field strength and is expressed as the ion mobility (K), with units of
cm2/sV .
Because IMS operates at atmospheric pressure, variations in drift time arise with
variations in ambient pressure and temperature. Accordingly, the mobility used is the reduced
mobility, corrected to standard temperature and pressure and calculated in Equation 5:

Equation 5
As an additional control on reduced mobility reproducibility, K0 of the analyte is expressed
relative to the reduced mobility of an internal calibrant [27] in Equation 6.

Equation 6
For work on GHB and analogs, the negative ion mode was selected based on sensitivity
to target analytes and on previously reported success with this method [28-29]. Instrument
response is based on competitive electron affinity and formation of negatively charged adducts
that are separated in the drift region based primarily on their size to charge ratio. Under
atmospheric ionization conditions, oxygen combines with electrons to form hydrated clusters of
the form (H2O)n O2- with n typically = 0,1, or 2. These are the reactant ion species present in the
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ionization region. Once sample (M) is introduced, charge competition and charge transfer occur
based primarily on gas phase electron affinity. The negative ions and ion/molecule clusters enter
the drift region and move toward the positively charged detector plate.
The broad appeal of IMS for the detection of explosives, drugs, and pharmaceuticals
makes its future inclusion as a regular instrument available in forensic laboratories likely. If so,
IMS has the potential to become an efficient screening tool for evidentiary samples in complex
matrices (such as biological fluids and beverages), particularly when immunoassay techniques
are not available. In this study, IMS was found to be sensitive (alarm response at 3ppm) and
selective for GHB analogs and GHV analogs in aqueous solutions and urine.
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Figure 1.3: Schematic of an IMS
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1.3.5: Gas Chromatography with Mass Spectrometric Detection
In addition to screening techniques, a standard confirmatory technique was needed to
complete a comprehensive suite of analyses for GHB and GHV. Gas chromatography-mass
spectrometry is a standard instrument for confirmatory testing in forensic laboratories and is
recognized by SWGDRUG as a suitable combination of Category A and B techniques as long as
information from both methods is used. In the gas chromatography (GC) used in this research,
the mobile phase is gaseous and the stationary phase is a tethered liquid inside of silicon
capillaries. Chromatographic separation is facilitated by the partitioning of analytes between the
stationary and mobile phases. As analyte moves through the capillary, analyte partitioning
reaches equilibria. In chromatography, retention time of an analyte is a factor of dead time (time
for the mobile phase to reach the detector) and time spent in the stationary phase.
A schematic of a GC is shown as Figure 1.4 composed of the following: a gas supply
(mobile phase); pressure regulaters, gauges, and flow meters to control and maintain a constant
flow rate; a sample injection chamber; a column contained in a thermostatted oven; and a
detector that is networked to a data collection system. For this research a quadrupole mass
spectrometer was used as a detector, a standard detector available in forensic laboratories.
A mass spectrometer consists of three zones: an ionization region, a mass analyzer, and a
detector. In this research, electron ionization (EI) was used to transition gas phase molecules to
gas phase ions for mass spectrometric detection. EI requires the use of an ion beam to react with
and ionize analytes as they exit the column. EI is classified as hard ionization (meaning
fragmentation is usual and may be extensive) which is useful for obtaining structural
information. The molecular ion M+ may form, but generally this ion contains too much energy
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and fragments, therefore, under reproducible conditions (70eV), EI spectra may be used to build
searchable databases of fragmentation patterns.
For mass analysis, a quadrupole mass analyzer was used to transport ions to the detector.
a quadrupole mass analyzer features four hyperbolic poles with oscillating applied DC and RF
potentials. The RF signal influences the trajectory of light ions while the DC signal influences
the trajectory of heavy ions. If an ion is destabilized by the oscillating signals, it will collide into
the quadrupoles and lose charge. Stable ions travel through the quadrupole to the detector. The
quadrupole mass analyzer may be scanned such that ions of varying mass to charge ratios arrive
at the detector to form a spectrum.
For detection, an electron multiplier was used. An electron multiplier is used to amplify
signal (with a typical gain of 106 to 1011 electrons) prior to arrival of electrons at a Faraday cup.
A Faraday cup is grounded and as electrons strike a current is generated and measured.
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Figure 1.4: Schematic of a GC-MS
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1.4.0: Metabolism of GHB
In addition to the comprehensive suite of analyses needed by forensic chemists to identify
GHB in forensic evidence, work was completed to enhance understanding of the metabolism of
GHB. Forensic toxicologists require more information about the coadministration of GHB and
ethanol in order to address the metabolism and observed effects in a court of law. Previous
studies have shown that coadministration of GHB and ethanol yield greater than additive
physiological effects. This may explain why victims of DFSA experience enhanced drug effects
when GHB is administered via alcoholic beverages. This research explored the possibility of a
competitive metabolic pathway for GHB and ethanol.
The effects of administered GHB, as a central nervous system (CNS) depressant, are
thought to be a function of its ability to mimic stimulation of the GABAA receptor due to its
structural homology with the endogenous ligand, γ-aminobutryic acid (GABA, Table 1.1). In the
brain, GHB is found endogenously at micromolar concentrations (human 11-25μM, rat 0.44.6μM) [30]. At such endogenous levels, the concentration of GHB is insufficient to activate the
GABA receptor and normal physiological effects are likely due to activation of a separate, yet
unidentified, G protein-coupled presynaptic receptor [31]. Reported GHB and GBL levels in
urine following administration of GHB range from above 1000ppm to 10ppm; 10ppm has been
designated as the accepted minimum limit for exogenous GHB in urine [10-11]. One exception
to the 10ppm limit has been established, the rare genetic condition GHB aciduria has been shown
to cause endogenous concentrations of GHB up to 260ppm in urine and is caused by a deficiency
of succinic semialdehyde dehydrogenase [11].
GHB metabolism is theorized to proceed via oxidation to succinyl semialdehyde (SSA),
and subsequently to succinate as shown in Figure 1.5 [32]. The metabolism of GHB may be
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mediated by three independent enzymes (A) a cytosolic GHB dehydrogenase, (B) a
mitochondrial transhydrogenase, and (C) fatty acid β-oxidation. These enzymes are found in the
liver and kidney.
In the cytosol, GHB is oxidized to SSA by enzyme A, GHB dehydrogenase (GHBDH,
EC 1.1.1.19) a cytosolic, NADP+ dependent oxidoreductase. This reaction may be coupled to
the reduction of D-glucuronate to make it more energetically favorable. Following are the
individual reactions and the energetically favorable coupled reaction that occurs in the cytosol
[33].
GHB + NADP + ←
→ SSA + NADPH + H +

(Km 2.2 x 10-3M)

D − glucuronate + NADPH + H + ←
→ NADP + + L − gulonate

GHB + D − glucuronate ←
→ SSA + L − gulonate

(Km 4.5 x 10-4M)

A second enzyme that is capable of metabolizing GHB to SSA is located in the
mitochondria. This enzyme, D-2-hydroxyglutarate transhydrogenase (a mitochondrial, αketoglutarate dependent transhydrogenase) is represented by B in Figure 1.5 and will hereafter be
referred to as GHB transhydrogenase (GHBTH) [32,34]. The mitochondrial reaction is shown
below.

GHB + α − ketoglutarate ←
→ SSA + α − hydroxyglutarate (Km 3 x 10-4M)
In both cytosol and mitochondria, SSA is further metabolized by succinic semialdehyde
dehydrogenase, to succinate. Succinate is then able to enter the tricarboxylic acid (TCA) cycle
for energy production [35].
Km values were reported using enzymes derived from hamster kidney homogenate.
However, it should be noted that similar values were measured in enzymes derived from brain
homogenate (Km 2.5 x 10-3M, Km 4.5 x 10-4M, and Km 3 x 10-4M respectively) [33]. The final
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pathway of GHB metabolism is via the fatty acid β-oxidation spiral, represented by C in Figure
1.5. However, studies in SSADH-/- mice indicate that this is not a major pathway for GHB
clearance and thus it is of limited interest for this study [32].
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Figure 1.5: Metabolism of GHB
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1.4.1: Coadministration of GHB and Ethanol
Several studies have explored the effects of coadministration of GHB and ethanol,
resulting in enhanced effects. This may explain why victims of DFSA experience potent drug
effects when GHB is administered via alcoholic beverages. This research explored the
possibility of a competitive metabolic pathway for GHB and ethanol accounting for the observed
effects.
Many of the current publications suggesting a pharmacokinetic or other interaction
between GHB and ethanol base their claims on behavioral studies. One early study by McCabe
et al. [36] focused on the sleep time of rats following administration of GHB, GBL, and ethanol.
Ten rats were injected with 6.51 mmole of ethanol per 100g of body weight. Four rats were
injected with 0.25, 0.33, or 0.41 mmole of GBL or GHB per 100g of body weight. A final four
rats were injected with 6.51 mmole of ethanol and 0.25, 0.33, or 0.41 mmole of GBL or GHB per
100g of body weight. The results of this study are shown as Figure 1.6. The effects of
coadministration were found to be greater than additive for GBL/ethanol and GHB/ethanol
combinations. The GBL/ethanol combination produced sleep times 2.3 - 4 times the sum of
sleep times while the GHB/ethanol combination produced sleep times 4 - 5 times the sum of
sleep times. Researchers theorized that since NAD is a cofactor in the metabolism of all
analytes, the competition for cofactor resulted in the increased duration of effect (sleep time)
[36]. The results of McCabe’s study suggest that coadministration of GHB and ethanol causes
an increased duration of the CNS depressant effects of one or both analytes. An increased
duration of effects is consistent with a common metabolic pathway, where the metabolism of one
analyte, presumably GHB, is hindered by the competitive presence of a second analyte, in this
case, ethanol.
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A later study by Hoes et al. [37] attempted to quantitate the effects of coadministration in
man. However, this study made the assumption that alcohol dehydrogenase (ADH) was
responsible for the metabolism of GHB. To date, this remains unconfirmed. Hoes et al. studied
excretion kinetics of GHB in control and alcoholic volunteers. Both groups showed first order
kinetics for excretion of GHB based on measurements of plasma samples. However, the
alcoholic volunteers eliminated GHB more slowly than the control volunteers. This resulted in
an increased area under the curve (AUC) for alcoholics. It should be noted that alcohol was not
given to the volunteers throughout the study. Hoes et al. concluded that the increased AUC was
due to some functional disorder in ADH but could not rule out the effects of GHB absorption or
distribution [37]. Given that ADH has not been shown to metabolize GHB, the results of this
study could be consistent with the existence of a separate metabolic pathway which functions to
metabolize both GHB and ethanol.
Sassenbroeck et al. [38] characterized coadministration of ethanol and GHB in rats. They
concluded, in agreement with previous studies, that the sleeping time of rats given GHB and
ethanol was significantly longer than the sum of sleeping times produced by individual analytes.
They then examined a possible pharmacodynamic interaction by investigating the influence of
varying concentrations of GHB and ethanol on three stimulus-responses (startle reflex, righting
reflex, and tail clamp). At high concentrations, a synergistic action was observed for the righting
reflex and an additive action was observed for the startle reflex. Thus the increase in sleep time
in this study was attributed to a pharmacodynamic interaction between GHB and ethanol [38].
This study is consistent with the results found by McCabe et al.; namely that coadministration of
GHB and ethanol produces increased durations of effects possibly due to a competitive
metabolic elimination.
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Thai et al. [42] attempted to characterize an interaction between GHB and ethanol in
humans. Sixteen subjects were given a 50 mg/kg dose of Xyrem (which is the FDA approved
Schedule III form of GHB used in clinical trials for the treatment of narcolepsy) and 0.6 g/kg
dose of ethanol. Plasma concentrations, heart rate, blood pressure, and oxygen saturation were
monitored for 24 hours after dosing. Although significant pharmacokinetic interactions were not
observed, coadministration did result in an increase in adverse affects on the gastrointestinal
tract, blood pressure (hypotension), and oxygen saturation (decreased O2 sat.). Coadministration
also produced an increased maximum concentration and longer half-life of GHB in plasma, but
these results were not statistically significant. The researchers suggested that drug interactions
may be more pronounced at increased dosages of GHB [39]. While the Thai study has some
aspects in common with the research discussed here, the project execution and data obtained
were different. While the Thai study relied on the behavioral effects of coadministration, this
research used enzyme kinetics to identify and measure a competitive interference of GHB by
ethanol. However, despite this and previous research, the mechanism of increased effects is not
complete.
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Figure 1.6: Sleep time of rats following administration of GBL, GHB, and ethanol

Reproduced with permission from reference [37].

32

1.4.2: Enzyme Kinetics
To assist toxicologists in testimony related to DFSA, enzyme kinetics were used to assess
any inhibition of GHB metabolism by ethanol. For this study, changes of Km and Vmax between
metabolism of GHB and metabolism of GHB in the presence of ethanol were assessed using a
Lineweaver-Burk plot. This enabled characterization of inhibition as competitive or
noncompetitive and measured the extent of inhibition. Further enabling conclusions to be drawn
regarding how coadministration of GHB and ethanol may impact drug users and victims of
DFSA in terms of increased effects and duration of action.
The velocity or reaction rate of a reaction is equivalent to the amount of product (P)
formed or substrate (S) consumed over time as shown in Equation 4, where k represents a
proportionality constant or rate constant (units s-1).
v0 =

d [ P] − d [ S ]
=
= k[ S ]
dt
dt

Equation 4

As shown below, an enzyme (E) and substrate molecule (S) come together to form a
complex (ES). While complexed, substrate is transformed by the enzyme to make the product
molecule (P) and the enzyme is released unchanged. The formation of ES occurs at a
measurable rate (k1), this reaction is reversible at a measurable rate (k-1). The rate of product
formation from the ES complex is expressed as k2 and this reaction is irreversible because
product can no longer enter the active site of the enzyme.
k1
k2
E + S ←→
ES →
E+P

The Michaelis-Menten equation allows the rate of a reaction to be expressed in terms of
substrate concentration. Michaelis-Menten kinetics are based on three assumptions:
1. Overall reaction velocity (v0) is limited by the formation of product, therefore v0 =
k2[ES].
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2. There is a constant concentration of ES because the rate of formation of ES is
equivalent to the rate of dissociation of ES, therefore k1[E][S] = k-1[ES]+ k2[ES].
3. Maximum reaction rate is achieved when the most E is associated with S, which occurs
when: [S] >>> [E].
An underlying expectation is that the concentration of enzyme remains constant because
enzyme is not changed or consumed by the reaction. The following two rate equations for
Michaelis-Menten Kinetics Equations 5 and 6 were developed:
v0 =

d [ P]
= k 2 [ ES ]
dt

Equation 5

v0 =

− d[S ]
= k1 [ E ][ S ] − k −1 [ ES ]
dt

Equation 6

Given the second assumption listed above, the rate of formation of ES is equivalent to the
rate of dissociation, shown as Equation 7 and referred to as the steady-state intermediate.

0 = k1 [ E ][ S ] − k −1 [ ES ] − k 2 [ ES ]

Equation 7

Given that the initial concentration of enzyme [E0] is equivalent to the concentration of
free enzyme [E] plus the concentration of complexed enzyme [ES] at any time after zero, [E0] =
[E] + [ES], then k1[E][S] = k1[E0][S] + k1[ES][S]. This can be substituted into the steady-state
intermediate (Equation 7) to create Equation 8:

0 = k1 [ E 0 ][ S ] + k1 [ ES ][ S ] − k −1 [ ES ] − k 2 [ ES ]

Equation 8

Equation 8 can be rearranged to make the following, Equation 9:

[ ES ] =

k1 [ E 0 ][ S ]
k1 [ S ] + k −1 + k 2

Equation 9

A further rearrangement, gives Equation 10:
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[ ES ] =

[ E 0 ][ S ]
k + k2
[ S ] + ( −1
)
k1

Equation10

As stated in Assumption 1, the overall reaction rate is expressed as v0 = k2[ES], which is
shown in Equation 11.
v0 = k 2 [ ES ] =

k 2 [ E 0 ][ S ]
k + k2
[ S ] + ( −1
)
k1

Equation 11

Further, the equation is shortened using Km which is a constant that is equivalent to the
ratio of constants (k-1 + k2) / k1. This final substitution yields Equation 12:

v0 =

k 2 [ E 0 ][ S ]
[S ] + K m

Equation 12

Figure 1.7 shows a graphical relationship between reaction velocity and substrate
concentration. Note that at the highest velocity, substrate concentration is saturated (all available
active sites on the enzyme are occupied by substrate). At this point, no addition of substrate can
increase the reaction rate. This velocity is referred to as Vmax. Also note that at half Vmax, the
Michaelis-Menten constant (Km) is equivalent to the concentration of substrate [S]. At Vmax,
enzyme is saturated and the concentration of substrate is much greater than Km, yielding
Equation 13:

Vmax = k 2 [ E 0 ]

Equation 13

Alternatively, we can rearrange Equation 12 to yield Equation 14:

v0
k 2 [S ]
=
[ E0 ] [S ] + K m

Equation 14

By inverting this equation, we receive Equation 15:
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[ E0 ] 1
K
=
+ m
v0
k 2 k 2 [S ]

Equation 15

Because Vmax = k2[E0], Equation 15 can be transformed into Equation 16, the
Lineweaver-Burk equation. This gives rise to the Lineweaver-Burk plot, which will be integral
to this study. Equation 16 is analogous to a line equation where y = mx + b. Using this equation,
1/ v0 represents the y-axis and 1/[S] represents the x-axis. The graphical representation of
Equation 16 is shown as Figure 1.8.

Km
1
1
=
+
v0 Vmax [ S ] Vmax

Equation 16

A central hypothesis of this work was that ethanol competitively inhibits the metabolism
of GHB based on their structural homology. This hypothesis was confirmed by metabolizing
GHB in the presence of ethanol and calculating the rate of inhibition. Competitive inhibition
occurs when both the substrate and the inhibitor compete for the same active site on the enzyme.
In reversible inhibition, the effects of inhibition can be mediated using substrate concentration.
If the concentration of substrate is much greater than the concentration of inhibitor, then the
likelihood of substrate binding enzyme is increased and less inhibition is seen. Consider the
follow system, where k3 is reversible at a measurable rate k-3.
k1
k2
E + S ←→
ES →
E+P
k3
E + I ←→
EI

It is assumed that formation of EI reaches a rapid equilibrium such that Equation 17 is
true and may be rearranged to make Equation 18. An enzyme-inhibitor dissociation constant
(KI) is defined as k-3/k3, which gives rise to Equation 19.

k 3 [ E ][ I ] = k −3 [ EI ]

Equation 17
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[ EI ] = (

[ EI ] =

k3
)[ E ][ I ]
k −3

[ E ][ I ]
KI

Equation 18

Equation 19

Equation 7 can be used to create Equation 20 as follows:

[ ES ] =

k1 [ E ][ S ] [ E ][ S ]
=
(k 2 + k −1 )
Km

Equation 20

Given that the initial concentration of enzyme [E0] is equivalent to the concentration of
free enzyme [E] plus the concentration of complexed enzyme [ES] and [EI] at any time after
zero, then [E0] = [E] + [ES] + [EI]. Equation 21 can be written using this relation and Equations
19 and 20, and rearranged to give rise to Equation 22.
[ E0 ] = [ E ] +

[E] =

[ E ][ S ] [ E ][ I ]
+
Km
KI

[ E 0 ]K m K I
( K m K I + K I [ S ] + K m [ I ])

Equation 21

Equation 22

Because v0 is defined as k2[ES], Equation 20 can be used to generate Equation 23 as
follows:

v0 =

k 2 [ E ][ S ]
Km

Equation 23

Using Equations 22 and 23, Equation 24 can be generated:

v0 =

[ E 0 ]K I k 2 [ S ]
( K m K I + K I [ S ] + K m [ I ])

Equation 24

Finally, because Vmax = k2[E0] then Equations 25, 26, and 27 can be generated:
v0 =

Vmax [ S ]
K [I ]
K m + [S ] + m
KI

Equation 25
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v0 =

Vmax [ S ]
[ S ] + K m (1 +

1
1
=
+
v0 Vmax

[I ]
)
KI

[I ]
)
KI
Vmax [ S ]

Equation 26

K m (1 +

Equation 27

If Equation 27 is used to generate the Lineweaver-Burk reciprocal plot, Figure 1.9
demonstrates competitive inhibition.
Noncompetitive inhibition can occur when an inhibitory compound does not interact with
the same binding site as the substrate. Thus the inhibitor can bind enzyme only (E) and enzymesubstrate complex (ES). Increasing the concentration of substrate (S) will have no effect on the
inhibition of the reaction.
KI
E + I ←→
EI
KI '
→ IES
ES + I ←

There are two types of noncompetitive inhibition, pure and mixed. In pure
noncompetitive inhibition, the inhibitor can bind E and ES equally well and KI = KI’. In mixed
noncompetitive inhibition, the binding of S or I can change the conformation of E and prevent
the other substance from binding. In mixed noncompetitive inhibition KI ≠ KI’. Figures 1.10
shows Lineweaver-Burk plots resulting from pure noncompetive inhibition.
Noncompetitive inhibition (pure or mixed) is not expected to be found between GHB and
ethanol because their structural homology indicates that both analytes would be suitable for the
same active site. If the inhibitor and substrate use the same active site, competitive inhibition is
seen. However, should noncompetitive inhibition be shown to explain the effects of
coadministration of GHB and ethanol as discussed above, it will be revealed using LineweaverBurk plots of substrate only and substrate plus inhibitor.
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Figure 1.7: Reaction velocity vs. substrate concentration
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Figure 1.8: Lineweaver-Burke plot
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Figure 1.9: Competitive inhibition
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Figure 1.10: Noncompetitive inhibition
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Chapter 2: Synthesis of GHV
2.1.0: Introduction
Although GHV was commercially available as a dietary supplement, the internet sites
that advertised it no longer list it as a product (as of March 24, 2010). Given the similar effects
of GHV and GHB (namely sedation, catalepsy and ataxia) GHV was suggested on some
websites as a replacement to protect users from the legal ramifications of owning and using the
DEA scheduled drug [5]. However, due to the increased dosage level the inherent toxicity of
GHV is a significant concern [4-5].
In 1988, Bourguignon studied the synthesis and pathway of effects of GHB and several
analogs (including GHV). He found that GHV inhibits receptor binding of GHB and concluded
that GHV binds to the same receptors as GHB. As GHV was not commercially available for
Bourguignon’s use, it was prepared by base hydrolysis of the lactone, GVL [4,40]. In 2005,
Carter shared the conclusion that GHV shares a receptor binding site with GHB. He also found
that although GHV does not share discriminative stimulus effects with GHB, it does share
behavioral effects at larger doses. He concluded that due to the higher dosage requirement, GHV
should be considered a toxic public health threat for its potential to replace GHB [5]. The
detection and characterization of GHV is an important issue in forensic toxicology and solid dose
analysis. Therefore, GHV was synthesized in-house to validate appropriate screening and
confirmatory tests to detect and distinguish GHB and GHV.

2.2.0: Experimental
2.2.1: Materials
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A solution of 99% GVL was obtained from Fluka (Ronkonkoma, NY). Sodium
hydroxyide (NaOH) was obtained from Fisher. NaGHV was synthesized via the hydrolysis of
GVL with NaOH (see previous Figure 1.1). Potassium bromide (KBr) and tetramethylsilane
(TMS) was purchased from Sigma-Aldrich. Deuterium oxide was purchased from Acros.
2.2.2: Instrumentation
The GHV synthesis method was confirmed using IR spectroscopy and H1 nuclear
magnetic resonance (H1NMR) to elucidate the structure of the reaction product (Figure 2.1). IR
was carried out on a Bruker Vertex 70 and data was collected using Optics User Software
(OPUS). H1 NMR spectra were obtained on a Jeol 270 MHz spectrometer and data was
collected on a Silicon Graphics INDY computer running DELTA NMR software.
2.2.3: Procedure
GVL (99%) and NaOH (0.1M) were mixed at a 1:1 mole ratio. The mixture was heated
for 3 hours with stirring. The remaining liquid was left overnight in a sonicator with gentle
heating. The resulting white, soapy precipitate was dried in an oven at 100°C for 1 hour. The
hygroscopic white solid was ground with mortar and pestle until powder like, washed with
acetone, and heated for a further 2 hours at 100°C. The sample was further ground to produce a
fine white powder.
IR spectra were collected from 32 accumulated scans at a resolution of 8 cm-1 over a
spectral range of 4000 – 400 cm-1. A pellet was made with a 10% mix of synthesized NaGHV in
KBr. To prevent the adsorption of water by the hygroscopic NaGHV, it was mixed with KBr and
the resulting powder placed in an oven at 100°C. The pellet was then made and returned to the
oven prior to analysis. Liquid GVL pellets were prepared by placing a droplet of 99% GVL on a
KBr disc.
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The H1NMR was operated with a probe temperature of 19.4°C and a spinner frequency of
15 MHz. A 45° pulse angle with 8 scans was applied for qualitative data collection. Wilmad 535
5mm x 178 mm sample tubes containing were used for data collection. As NaGHV was
insoluble in chloroform and carbon tetrachloride, a 1000ppm solution of NaGHV was made in
deuterium oxide containing tetramethylsilane (TMS) as the internal standard. A similar mix of
GVL and deuterium oxide was analyzed but one peak was obscured by water; so further analysis
was done on a solution of GVL in chloroform.

2.3.0: Results
2.3.1: IR Analysis of the GHV Standard
Confirmation of structure was made by comparison with literature reported IR analysis of
GHB, GHV and GBL [41]. The IR spectrum of GVL (Figure 2.1) features a sharp peak at 1773
cm-1 which can be attributed to the carbonyl stretching mode and is a typical absorption for a
cyclic carbonyl. The broad feature at 3528 cm-1 is consistent with carbonyl stretching modes.
The sharp peaks at 2981cm-1 and 2936 cm-1 are due to carbon-hydrogen stretching modes. The
peaks below 1450 cm-1 are largely attributable to other stretching modes of the carbonyl group
[41].
Given the hygroscopic nature of NaGHV, the resulting IR spectra (Figure 2.2) features a
low base line with a very broad feature from 3600 cm-1 to 2900 cm-1. Although precautions were
taken to exclude moisture, the nature of IR analysis involved exposing the sample to atmospheric
conditions for the duration of the analysis. Alkyl carbon hydrogen stretching accounts for the
features seen at 2930 cm-1 and 2960 cm-1. A pair of sharp peaks observed at 1127 cm-1 and 1079
cm-1 is consistent with the carbon-oxygen stretching mode of a secondary alcohol.
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Notable differences between the two spectra include the disappearance of the carbonyl
stretching peak at 1773 cm-1 in the spectrum of GVL with the emergence of a broad peak at 1580
cm-1. The position of the lower wavenumber peak is indicative of carboxylic acids due to a
weakening of the carbonyl bond from hydrogen bonds in the condensed state. This effect is more
pronounced in NaGHV due to the formation of the carboxylate anion, where delocalisation of the
carbonyl pi-bond further lowers the stretching frequency of the carbon-oxygen bond [41].
2.3.2: NMR Analysis of the GHV Standard
Results of the NMR analysis of synthesized GHV are shown in Figure 2.3. Four
hydrogens were identified: Hα, Hβ, Hγ, and Hδ. Hα presented as a triplet of doublets due to
splitting caused by 2 Hβ and 1 Hγ. Hβ presented as a quartet caused by splitting from 2 Hα and 1
Hγ which were not differentiated into secondary splitting. The complex splitting of Hδ is best
explained by diastereotopic hydrogens. GHV features a chiral center at the δ carbon. These
results were compared to NMR analysis of the starting material, GVL (Figures 2.4 and 2.5).

2.4.0: Conclusion
GHV has been called an emerging public health concern due to its ability to replace the
effects of GHB at higher dosage levels. Unfortunately, GHV is no longer commercially
available. To facilitate development of analyses, NaGHV was prepared using published methods
via the hydrolysis of lactone to free acid. Conversion was confirmed by spectroscopic methods
including H1NMR and IR.
IR analysis revealed several differences between the lactone starting material and the free
acid product. GHV is revealed to be highly hygroscopic. Peaks in the IR spectra are consistent
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with the carbon-oxygen stretching of secondary alcohols. The shift of the carbonyl peak
indicates a conversion from a cyclic molecule to an acid.
This solid white powder was used to develop novel screening techniques for GHV (and
GHB) in beverages and biological fluids. In addition, a GC-MS method was validated for
separation of GHB and GHV and confirmation of drug identity.
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Figure 2.1: IR spectra of GVL
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Figure 2.2: IR spectra of synthesized GHV
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Figure 2.3: H1NMR spectra of synthesized GHV in deuterium oxide
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Figure 2.4: H1NMR spectra of GVL in deuterium oxide
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Figure 2.5: H1NMR spectra of GVL in chloroform
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Chapter 3: Chemical Composition and Structure of the
Microcrystals Formed Between Silver(I) and GHB and GHV [42]
3.1.0: Introduction
This work was published in 2006 in the Journal of Forensic Science [42]. Of interest is
the confirmation of a screening technique (crystal testing) for both GHB and GHV. The matrix
in which drugs such as GHB are delivered is often complex and colored, making it difficult or
impossible for detection by traditional screening tests based on color changes. Even if a color
test is feasible and yields a positive result, color differences are not commonly associated, even
anecdotally, with specific compounds. GHB provides a case in point. Many of the color test
reagents used to screen samples for this drug are acid/base indicators [2] that target the weak acid
character of GHB. A positive result, even when it can be obtained, is only marginally
informative in comparison with information provided by a positive microcrystal test. However,
this is only true when crystal morphology can be unambiguously assigned to the specific drug or
analyte in question.
Following reports of microcrystals formed by γ-hydroxybutyric acid (GHB) in copper
solutions, this laboratory sought to use crystal testing to identify and distinguish GHB, γhydroxyvaleric acid (GHV), and their respective lactones in both neat and solution forms. GHV
was included as it appears to be an emerging drug threat similar to GHB that is likely to present
similar analytical challenges [5]. The closed-ring lactone forms of GHB and GHV (GBL, γbutyrolactone and GVL, γ-valerolactone respectively) were also tested since some fraction of the
drug will be in the closed form depending on the pH of the matrix [41,43-44].
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The crystal test reagents selected were ones previously reported as useful for GHB and
included a silver/copper reagent [43]. Andera described the use of a solution containing 1% of
each Ag+ and Cu2+ tested with GHB and related 4-carbon compounds as well as with other drugs.
Distinctive crystals were produced for GHB within 5 minutes at the periphery of the drop with a
reported detection limit of approximately 2.0 mg/mL (0.1% w/w). No crystals formed with
GBL. A report was located referring to a lanthanum reagent [45], although the reference was
described on a webpage that provided little specific information. The webpage has since been
removed, but lanthanum is a logical choice for crystal testing given its size and charge.
Therefore, it was included for evaluation.
In the present study, distinct microcrystals formed with silver (+1) and lanthanum (+3)
ions but not with copper (+2) ions. Crystal formation was seen as low as 0.01% w/v GHB and
GHV. The crystals formed with GHB were visually distinct from those formed with GHV and
reagent crystals. The morphological differences between the silver-GHB and silver-GHV
crystals were characterized using size and angles measurements provided by image recognition
software enabling objective identification.
A key goal of the present study was the unambiguous assignment of chemical
composition and structure of microcrystals. One effective method to characterize a crystal is Xray diffraction (XRD). This crystallographic method works well with large atomic weight atoms
such as gold, platinum, silver, and copper that are used in many forensic microcrystal tests.
Although XRD has been used in forensic applications [46-52], surprisingly a literature search
failed to identify any studies in which this technique has been applied to microcrystals of interest
or current use in forensic chemistry. In this study, XRD confirmed the incorporation of the free
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acid forms of GHB and GHV in the crystal matrix. Given the literature search, it is believed that
this is the first instance of drug crystal confirmation by XRD.
XRD can be conducted on powders or using a single ordered crystal as was the case here.
Exposing the crystal to x-ray radiation generates a series of internal reflections and interactions.
The resulting patterns of constructive and destructive interaction can be related to unit cell
structure and this was the technique incorporated here. The large crystals formed by silver and
GHB or GHV were proven to have incorporated the drug into the crystal cell structure in an
orderly and reproducible fashion.
Upon confirmation of the efficacy of the crystal test, the utility of the test for casework
was demonstrated using spiked beverage samples. Crystal testing was found to be effective for
many types of beverages, but for wine, beer, and some mixed drinks, some type of additional
sample extraction and preparation will be needed before the method can be generally applied to
casework.

3.2.0: Experimental
3.2.1: Materials
GHB, GBL, and GVL were purchased from Sigma Aldrich. GHV was synthesized inhouse from GVL and the identity confirmed using IR and H1NMR analysis (Chapter 2). Crystal
reagents were purchased from Sigma Aldrich (silver nitrate and cupric nitrate) and Fluka
(lanthanum nitrate). Methanol (MeOH) and sodium chloride (NaCl) were purchased from J.T.
Baker. Hydrochloric acid (HCl) was purchased from Fisher. Chloroform was purchased from
EMD. Beverage materials included: water, Tropicana® cranberry juice cocktail with Barton®
vodka (1.5oz vodka and 10.5oz cranberry juice), Coca Cola®, Guinness Stout® beer, Coors
Light® beer, and Willi Haag® Riesling (2003). All beverages were obtained from local stores.
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3.2.2: Instrumentation
The solutions of analyte and reagent on the slide were dried at room temperature and
examined using a Leica DMLP polarizing microscope at a total magnification of 100X.
Photographs were taken using a QICAM QIMAGING Fast 1394 camera using Image Pro Plus®
software. Individual crystals were isolated using micromanipulation techniques and diffraction
data was obtained with a Siemens P4 diffractometer equipped with a CCD detector and then
analyzed using SHELXTL crystallographic software.
3.2.3: Procedure
The crystallizing reagents used are summarized in Table 3.1. All were prepared from
solid standards [44] at a concentration of 1.0% (w/v) for the ion from nitrates and hydrated
nitrate salts. For initial testing, solutions of 1000ppm GHB, GHV, GBL and GVL were prepared
in methanol and distilled water. Methanol was originally used to speed drying of the crystals,
but was abandoned due to excess spreading on the microscope slides.
Case samples were simulated using a light beer, Coca Cola®, Sprite®, a white wine, and
mixed drinks consisting of vodka/cranberry juice and tequila/ Sprite®. Samples were spiked at
1.0% of GHB and GHV (separately) and tested at this concentration and at dilutions as described
below. The stock and diluted samples included the concentrations typically seen in drug
facilitated sexual assault cases [43].
Extractions of the simulated case samples were performed using a previously published
extraction technique [41]. Approximately 5 mL of the sample was placed in a large test tube and
acidified to a pH of 2-3 using dilute HCl and measured using 0-14 pH paper. The acidified
solution was extracted with chloroform and the organic layer discarded. The aqueous layer was
saturated with NaCl and extracted with ethyl acetate. The ethyl acetate portion was dried with
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gentle heating. Success of the extraction of the spiked samples was verified using a validated
HPLC analysis [6,53]. Briefly, a Hydrobond AQ column (4.6mm x 15cm x 5µm) was held at
30°C. The mobile phase was 95:5 50mM phosphate buffer (pH 3):MeOH at 0.5mL/min. 10µL
were injected. A wavelength of 215nm was used for detection.

3.3.0: Results
3.3.1: Crystal Formation
Distinctive rectangular-shaped crystals were observed for GHB samples with reagents
containing silver (Figure 3.1) and lanthanum (Figure 3.2). Distinctive parallelogram-shaped
crystals were observed for GHV samples with reagents containing silver (Figure 3.3) and
lanthanum (Figure 3.4). No crystals formed using copper ion alone, nor were crystals formed
when the solution of all three ions was used. The microcrystals observed in this study match the
descriptions and dimensions of those reported in the earlier work [43]. No crystals formed for
either of the lactones (GVL and GBL) with any of the microcrystal reagents. Representative
photomicrographs are as shown as Figures 3.1 – 3.4.
Generally, the crystals formed within 10 minutes and developed from the periphery of the
drop. The crystals persisted when dry; indicating that the time to observation is not a critical
variable. The crystals formed in the presence of lanthanum were too fragile to transfer to the
XRD and were not studied further. This fragility may be attributable to a less stable crystal
structure resulting from the insertion of a +3 ion in the lattice, but this hypothesis could not be
explored or confirmed. All subsequent work undertaken and described utilized the 1% solution
of silver nitrate.
Contrary to the earlier report [43], the presence of copper ion was not required for crystal
formation; microcrystals formed readily with reagents containing only silver nitrate and only
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lanthanum nitrate. This may be related to different methods of reagent preparation. The present
work used nitrate salts as starting materials whereas the earlier work relied on a copper nitrate
derived from a copper chloride solution. This solution was treated with silver nitrate to
precipitate out the chloride as AgCl, but silver ions likely remained in the solution. Regardless,
the description of the GHB microcrystals from this earlier work closely matches what was
obtained here.
3.3.2: Crystal Measurements
The width of the GHV and silver crystals (Figure 3.3) was typically larger (40-60 um)
than those associated with GHB and silver crystals (Figure 3.1) (20-40 um), particularly early in
the crystal formation process. Some of the GHV crystals developed ragged terminal edges in the
latter stages of development. Crystals were also observed with reagents alone, but these
dendritic (copper/silver metal), rhombus, and hexagonal shaped crystals were distinctly different
from those generated in the presence of the drugs. In all trials, 3-5 separate slides were prepared
as replicates and photomicrographs of several crystals at different reagent concentrations were
studied to generate measurements as summarized in Table 3.2.
3.3.3: XRD Analysis
Structural analysis using XRD revealed that in the case of the GHB crystal, the
asymmetric unit within the unit cell consist of two Ag+ and two chelating GHB anions producing
a dimeric [Ag (O2CCH2CH2CH2OH)]2 unit (Figure 3.5). This dimeric molecular unit is
connected to adjacent [Ag (O2CCH2CH2CH2OH)]2 units via a pair of Ag-O bonds. This
arrangement affords an extended, nearly planar molecular strand directed parallel to the facial
plane of the crystal lattice. The immediate coordination geometry about each Ag+ is pseudosquare planar. The four atoms bonded to each Ag+ ion consist of a carboxylate O atom from
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each chelating butyrate ligand, the other silver atom, and a bridging carboxylate O atom from an
adjacent symmetry-related dimer.
The molecular strands are held together by intermolecular hydrogen bonds between the
terminal hydroxyl groups located at the perimeter of each strand. The resultant three
dimensional structures consist of layers of these hydrogen bonded strands, and is further ordered
by weaker Ag-O interactions between parallel layers. The structure is highly organized and
shows no indication of disorder within the lattice.
In the case of GHV, the crystallographic asymmetric unit consists of 3 Ag+ and 3 GHV
anions producing a trimeric [Ag (O2CCH2CH2CMeHOH)]3 unit (Figure 3.6). The solid state
structure of this system is comparable to that observed for the Ag-GHB analog. However, the
hydrogen-bonding network between the terminal hydroxyl groups of adjacent strands is
disrupted by the crystallographic disorder of the chiral CHMeOH group for two of the three
GHV chelating ligands. The spatial arrangement of atoms about each Ag is also pseudo-square
planar and weak Ag-O interactions similarly exist between the parallel layers within the lattice.
The presence of the methyl group of the GHV anion lowers the overall lattice symmetry from
monoclinic for [Ag (O2CCH2CH2CH2OH)]2n to triclinic for [Ag (O2CCH2CH2CMeHOH)]3n, thus
explaining the difference in morphology (rectangle vs. parallelogram) for GHB and GHV
respectively.
The behavior of the crystals under crossed polars was consistent with their thin plate
structure. They appeared grey and showed maximum brightness at 45°, as can be seen with
some of the crystals shown in Figures 3.1 – 3.4. A Michel-Lévy chart relates thickness,
retardation of light, and birefringence of colorless or lightly colored substances. The relation of
these characteristics provides important optical information. Retardation is proportionally
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related to thickness and birefringence. Birefringence refers to substances that have two
refractive indices. The greater in difference between the two refractive indices; the greater the
retardation of light will be. Using a Michel-Lévy chart, if two characteristics are known, the
third can be inferred [17]. In this study, a Michel-Lévy chart was used to compare crystals to
infer that the Ag-GHB structure was thicker than the Ag-GHV. Knowledge of the crystal
structure explains why the lactone (ring) forms of the two drugs did not form the characteristic
crystals. An open chain form is required for the drug moiety to be incorporated into the crystal.
The pH of the crystal test reagent was nearly neutral and not sufficiently basic to drive the
lactone ring to open. In no case was copper or lanthanum detected in the crystal structure.
Given that the crystals formed in the presence of silver ions alone were indistinguishable from
those formed when other ions were present, it is unlikely that either of the other ions (lanthanum
or copper) were ever incorporated in the crystal structures.
3.3.4: Beverage Analysis
Analysis of spiked water samples using silver solutions showed the distinct crystals
observed previously for GHB and GHV over a concentration range of 1% to 0.01% (w/v of the
drug). Distinctive crystals were also observed in the sodas (Coke® and Sprite®) and the
Sprite®/tequila drink, but not in the wine, beer, or the mixed drink sample of vodka and
cranberry juice. To remove interfering components, the beer, wine, and mixed drink samples
were extracted as previously described by acidification, chloroform wash, and ethyl acetate
extraction.
Success of the extraction of the spiked samples was verified using a validated HPLC
analysis [6,53] which showed two peaks consistent with GHB and a smaller GBL peak.
However, when the residue was re-hydrated and drop tested with silver nitrate solution, no
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characteristic crystals were seen despite repeated attempts. It is possible that the extraction
procedure concentrated the GHB/GHV as well as substances that interfered with crystal
formation. Sugars are one possibility that would not be detected using the HPLC method applied
here.
Further attempts to produce crystals using a toluene wash of the samples [43] and dilution
were also unsuccessful. An important clue to the observed problems may lie in the initial tests
which showed that the tequila and Sprite® drink produced crystals while the mixed drink
consisting of cranberry juice and vodka did not. It is conceivable that juice and related
fermentation products such as beer and wine contain extractable compounds at sufficient
concentrations to inhibit or interfere with crystal formation.

3.4.0: Conclusion
Microcrystal tests can fulfill a niche as presumptive tests when other screening
techniques are not feasible, such as color testing and EMIT. Currently crystal tests are
considered presumptive and subjective; thus they have become less commonplace in forensic
laboratories where they are replaced by instrumental methods. At one point, crystal tests were
considered not only confirmatory, but one of the most specific tests available for certain drugs of
abuse given the unique crystals formed. If crystal tests were shown to be highly selective, it is
more likely that crystal based screens would be reintroduced in laboratories. XRD is classified
as a SWGDRUG category A technique [14]; which can be used to positively determine the
atomic arrangement of a crystal and associate crystal morphology with a specific drug. This
laboratory was the first to publish confirmation that XRD analysis could be used to validate the
uniqueness of drug crystals; future work on common drugs and crystaling agents could ensure
microcrystal testing is no longer presumptive but conclusive. The key is the ability analysts use
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to recognize the crystal and apply quantitative measures such as size and angles to verify analyst
interpretation.
References were found suggesting copper and lanthanum as effective crystallizing agents
with GHB. However the reported copper solution was created using silver nitrate, thus silver
was also tested as a crystallizing agent. Silver and lanthanum were shown to be effective for the
crystallization of GHB and GHV. Methanol based solutions of GHB were shown to dry quickly
but spread undesirably across the slide. Therefore, reported testing was completed on aqueous
solutions.
Here, it was possible to identify GHB and GHV in some complex matrices and to clearly
differentiate the two based on crystal morphology. GHB produced square crystals while GHV
produced parallelogram crystals with both silver and lanthanum at concentrations as low as
0.01% w/v of the drug in solution. Lactones, GBL and GVL, did not produce crystals. Reagent
crystals were seen but were readily distinguishable from analyte crystals based on morphology.
XRD confirmed incorporation of the GHB and GHV molecule into analyzed crystals.
GHB crystals featured pseudo square planar silver molecules in highly organized monoclinic
crystals that presented as rectangular to the naked eye. GHV crystals also featured pseudo
square planar silver molecules but the presence of the chiral methyl group caused disorder that
interfered with hydrogen bonding. Thus GHV crystals are classified as triclinic and present as
parallelograms to the naked eye. GHB-silver crystals were shown to be thicker than GHV-silver
crystals using polarized light microscopy. This difference in thickness could be related to greater
interplanar hydrogen bonding and decreased disorder of GHB-silver crystals.
Microcrystal analysis was applied to beverages. Crystal formation was seen for samples
of sodas and liquors, but wine, beer, and juices require, some type of additional sample
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extraction and preparation before the method can be generally applied to casework. Extractions
attempted here were ineffective at producing crystals in these beverages, possibly because of
concentration of crystal interferents.
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Table 3.1: Crystal test reagents
Single ion (0.1% w/v)

Combined ions (1% each w/v)

Ag+

Ag+ and Cu2+

Cu2+

Ag+ and La3+

La3+

La3+ and Cu2+
Cu2+ / Ag+ / La3+
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Table 3.2: Crystal descriptors
Average

Confidence
Standard

Sample

Shape

Internal Angle

%RSD

interval

deviation
(n=7)

(95%)

GHB(1000ppm)
90.4o

0.59

0.66

±0.50

Acute: 49.3o

1.74

3.56

±1.6

Obtuse:126.0o

1.03

0.81

±0.95

Rectangular

89.9°

0.39

0.44

±0.29

Parallelogram

N/A

N/A

N/A

N/A

Rectangular
AgNO3/CuNO3
GHV(1000ppm)
Parallelogram
AgNO3/CuNO3
GHB (5000ppm)
AgNO3/LaNO3
GHV (5000ppm)
AgNO3/LaNO3*

*Crystals formed were irregular with many appearing broken. Angle measurements were not
possible.
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Figure 3.1: Microcrystal testing: GHB and Ag+
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Figure 3.2: Microcrystal testing: GHB and La+3
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Figure 3.3: Microcrystal testing: GHV and Ag+
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Figure 3.4: Microcrystal testing: GHV and La+3

69

Figure 3.5: XRD analysis: GHB and Ag+
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Figure 3.6: XRD analysis: GHV and Ag+
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Chapter 4: Application of Ion Mobility Spectrometry (IMS) to the
Analysis of GHB and GHV in Biological Matrices [54]
4.1.0: Introduction
This research was published in the Journal of Analytical Toxicology in 2006 [54] and
was awarded as a Selected Article on the Analysis of Drugs of Abuse in Biological Specimens
(July – December 2006) by the United Nations Office on Drugs and Crime. This research sought
a rapid and reliable screening test for detection of GHB and GHV which would be useful for
toxicologists as well as forensic chemists working with solid dose samples, beverages, and
bodily fluids. Currently GHB is not amenable to common screening techniques used in forensic
laboratories including EMIT and color testing. This lab had previously confirmed the
effectiveness of a microcrystal test effective for screening aqueous solutions [42], but felt the
development of a rapid, simple instrumental test effective for screening complicated,
toxicological matrices (urine and breath) would be of use to the forensic community. To this
end, ion mobility spectrometry (IMS) was investigated as a method of screening urine and breath
for the presence of GHB, GBL, GHV, and GVL. IMS shows promise as a rapid, simple, and
affordable screening technique for GHB and GHV in biological fluids.
GHB and GHV are extremely hygroscopic and hydrophilic, this hinders the effectiveness
of tested extractions that might be needed for quick screening of complicated matrices such as
beverages and biological fluids. Thus, any successful GHB/GHV screening methodology must
either be matrix independent or insensitive or capable of rapid and semi-quantitative extraction
from the matrix. The latter issue has been the limiting factor to date.

72

In the present study, a high-performance split/splitless injector and autosampler were
utilized to effect a physical separation of GHV and GHV from aqueous matrices (including
urine) based on differences in relative volatility. This is achieved by a timed period of solvent
evaporation following by rapid temperature increase and thermal desorption of the residuals.
Sample was introduced directly into a detection system without any chromatography, resulting in
rapid analysis times. The detection system used was ion mobility spectrometry (IMS).
Any technique for detection of GHB in urine would require sensitivity to 10ppm (the
established maximum limit of endogenous GHB in urine) [11]. In this study, the negative ion
mode showed the greatest sensitivity with alarm response in the low parts-per-million range for
GHB and GHV. Since GHB may be delivered in alcoholic beverages, ethanol and acetaldehyde,
along with potential interfering compounds methanol, isopropanol, and acetone, were also
analyzed. None were found to interfere.
In addition to screening of urine, IMS was tested for its suitability as a breath monitor.
GHB and GHV samples were evaporated onto a Teflon® pad for analysis. Given the portability,
ease of use, and affordability of IMS, optimizing it to detect controlled substances in breath
could make it a powerful tool for law enforcement agencies.

4.2.0: Experimental
4.2.1: Materials
GVL and GBL (in liquid form at 99% purity) were obtained (Fluka, Ronkonkoma, NY)
as was solid GHB and of BD (in liquid form at 99% purity) (Sigma-Aldrich, St. Louis, MO).
GHV was synthesized via the hydrolysis of GVL with NaOH (Chapter 2). Synthetic urine
concentrate was obtained (Ricca Chemical Company, Arlington, TX) and diluted 1:10 with
deionized water. This solution was used for design and optimization of the experimental
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parameters. The Teflon® filters used were 2μm PTFE 46.2mm filter (Whatman, Clifton, NJ).
Interferents were obtained from Sigma-Aldrich (ethanol, acetone, acetaldehyde, and isobutanol)
and J.T. Baker (methanol). The absorbent pads used for headspace sampling were Teflon filter
membranes.
4.2.2: Instrumentation
The instrument used in this study was an Ionscan® - LS (Smiths Detection, Danbury,
CT). A schematic of the injection system is shown in Figure 4.1. Drift times and reduced
mobilities of the target compounds were determined using direct introduction of neat solid or
liquid materials onto the Teflon membrane labeled “A.” The resulting mobility spectra were
used to define the mobility ranges and peak widths for each analyte. Instrumental parameters
and settings are provided in Tables 4.1, 4.2, and 4.3.
4.2.3: Procedure
Saturated solutions of GHB and GHV were made in deionized water and synthetic urine
and the saturated solution concentration was estimated based on structural modeling at 8M.
These saturated solutions were used to optimize system parameters. Serial dilutions were used to
determine limits of detection in water and urine. Saturated solutions were diluted 1:5 in 5 serial
dilutions. The lowest concentration solution was diluted 1:10 for an additional 2 serial dilutions.
These 7 dilutions were done using both deionized water and urine.
Aqueous samples were introduced via the high-pressure injections (HPI). Solutions were
first introduced to the sample chamber where water was evaporated at 200°C and vented for 20
sec. Remaining sample was then introduced onto a Teflon® substrate. The IMS method was
triggered by the HPI, beginning desorption at 300°C and introduction of gas into the reaction
region. The inlet and drift tube temperatures were 300°C and 111°C respectively. Drift tube
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flow was set to 351cc/min. These HPI settings were adapted from a standardized Aqueous
Sample method provided by Smith’s Detection.
To test the suitability of IMS for breath sampling, headspace sampling was done in the
following manner. 3μL of saturated GHB or GHV solution was placed in a 1.5mL vial. The vial
was heated to 70°C using a sand bath. An absorbent Teflon® pad was placed over the heated
vial. Alternatively, solid samples of GHB and GHV were placed in a 1.5mL vial and heated to
100°C which were then similarly sampled. The absorbent pad was loaded on the sliding stage in
lieu of the Teflon® filter and analyzed using the same method used for solid dose analysis.

4.3.0: Results
4.3.1: Analysis of Neat Analyte
Reduced mobilities of GHB, GHV, GBL, GVL, and BD were determined by direct
analysis of solid samples on a Teflon® filter. Resulting Ko’s are shown in Table 4.4. GHB,
GBL, and BD were indistinguishable based on Ko’s and standard IMS alarm variability (standard
is ±50µs in drift times). Very slight differences in the reduced mobilities of GHB and GBL were
noted, consistent with earlier results [29].
Figure 4.2 illustrates several features of interest. The first few mobility spectra reflect
conditions after the solvent has been boiled off by the HPI but before sample is introduced. As
the desorption temperature increases, vapors enter the ionization and drift regions, resulting in
charge re-distribution as described previously. A peak emerges at a drift time of about 10
milliseconds attributed to GBL. Over time, additional vapors enter the instrument, increasing
this peak intensity. Accompanying this, additional peaks appear at longer drift times,
corresponding to larger ions. The peak seen at ~ 14 ms is likely the GBL dimer and the peak at
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16 ms could be a trimer. However, such identifications are tentative and not critical for the
current application.
To estimate the limits of the IMS alarm system for GHB and GHV, solutions of both
were prepared to saturation at an estimated concentration of 8M. Serial dilutions were conducted
and based on the alarm settings, the detection of GHB and GHV was possible at approximately 3
ppm. This detection limit was consistent with an earlier IMS analysis of GHB and GBL in
beverages. To add ensure the application of our method to beverages, potential interferents
(ethanol, acetaldehyde, methanol, acetone, and isopropanol) were also analyzed in neat form and
found to have drift times that did not coincide with the GHB, GHV, or the lactones. Most likely,
these compounds are removed during the evaporation phase of the HPI method.
4.3.2: Urinanalysis
To gauge applicability in toxicology, GHB and GHV were dissolved in saturated
synthetic urine solutions followed by serial dilutions as described previously. In synthetic urine
the alarm responded to a concentration of 3 ppm in urine, again by serial dilution methods. As in
solution, GHB and GHV are distinguishable from each other in synthetic urine. Figure 4.3 shows
the results of IMS analysis of GHB. Figure 4.4 shows a similar analysis of GHB in synthetic
urine. Figure 4.5 shows the results of IMS analysis of solid GHV. Figure 4.6 shows a similar
analysis of GHV in synthetic urine. Although the urine matrix contributes an additional
background peak around the 15ms drift time, the peaks for GHB and GHV remain discernible.
4.3.3: Headspace Analysis
Finally, two methods were employed to evaluate the feasibility of detecting GHB and
GHV in the gas phase and potentially in breath. In the first case, 3.0 µL of saturated aqueous
solution was heated in a sand bath to ~70°C and the vapors collected on a Teflon substrate.
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Response was seen for GHV but not GHB. Similar results were noted for headspace above neat
solid samples heated to 100°C. An example GHV response is shown in Figure 4.7. These
results clearly show that these compounds are not amenable to breath alcohol type protocols.
However, other bodily fluids, such as saliva, may be a more promising matrix.

4.4.0: Conclusion
This research sought to characterize rapid and reliable screening techniques that could be
implemented in forensic laboratories using commonly available equipment. GHB is not
amenable to traditional screening methods (color testing and EMIT) which could contribute to
poor detection in DFSA cases. Given the popularity of IMS for homeland security and forensic
applications, it is possible that an IMS screen could become a standard presumptive test for
samples in toxicological and controlled substance laboratories, especially for cases of DFSA.
As GHB is extremely hygroscopic, it is difficult to extract from solution. Key to the
success of IMS as a GHB screen is the use of a high performance split/splitless injection system
to effect a physical separation of the analytes from aqueous samples based on differences in
boiling point and volatility. In addition, HPI introduction enabled IMS detection of GHB
without interference from possible beverage and urine components.
Analysis of pure material was used to confirm the suitability of IMS to detect GHB,
GBL, GHV, and GVL and distinguish GHB/GBL from GHV/GVL. Although the acid and
lactone are not readily distinguishable at common alarm selectivity, future studies may exploit
the slight change in mobilities seen in this and a previous study. Another area of future work
would be identification of possible dimer and trimer peaks seen during analysis of neat solid.
Coupling IMS separation to a detector capable of structural determination (such as mass
spectrometry) would be effective.
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Endogenous levels of GHB in urine are accepted as lower than 10 ppm. Serial dilutions
of saturated solutions and urine samples show that common IMS alarm settings are effective at 3
ppm for detection of GHB and analogs. This alarm sensitivity is appropriate for toxicological
urinalysis. Although some components of the synthetic urine produced peaks, none were found
to interfere with GHB and GHV detection.
IMS was also investigated for use in breath analysis of GHB and analogs. Headspace
samples of pure solid and saturated solutions were analyzed but poor response was seen. It
appears GHB and analogs are insufficiently volatile to produce an absorbable vapor response
using absorbent Teflon pads. Therefore, IMS analysis may be further investigated for use on
solutions, but it is unlikely that GHB and analogs are amenable to future breath testing.
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Table 4.1: Instrument parameters for IONSCAN®-LS
Desorber temperature
Inlet temperature
Drift tube temperature
Analysis time
Calibrant ion
Width of the spectrum
Drift gas flow
Sample gas flow
Drift and sample gas

300°C
300°C
111°C
12 s
Chloride
20 ms
351 cc/min
200 cc/min
Purified ambient air, estimated
moisture content of 5-50ppm
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Table 4.2: Data acquisition parameters (negative ion mode)
Analysis delay following desorption
Scan period
Shutter grid width
Maximum analysis duration
Maximum number of segments per analysis
Number of co-added scans per segment
Analysis duration
Number of segments per analysis
Delay before start of sampling
Sampling period
Number of sample points per scan
Delay to start of background reference
Duration of background reference

0.025 s
20 ms
0.200 ms
12.0 s
60
10
12.0 s
60
1.0 ms
50.0 µs
379
5.0 ms
0.750 ms
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Table 4.3: HPI parameters
Timeout (min)
Injector Temperature Control
Standby Temperature
Standby transfer line flow
Standby Split Valve State
Standby Split Flow
Injector Cooling
Transfer Line Temperature Control
TL Temperature
Internal Line Diameter
Transfer Line Length
Carrier Gas

15 min
YES
50°C
0.50 mL/min
Splitless
50.0 mL/min
OFF
YES
280°C
0.10 mm
0.080 m
N2
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Table 4.4: Average reduced mobilities of main peak of neat analyte
Analyte
GHB
GHV
GBL
GVL
BD

Peak 1 (Ko)
1.7097
1.6190
1.7105
1.6380
1.7103
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Figure 4.1: Schematic of the injection chamber of the IMS

HPI injections are deposited by the syringe onto Target B (a Teflon® block). Sample is heated
at 200°C and vented to remove water. Remaining analyte is desorbed at 300°C and transferred
to the IMS via a heated transfer line.
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Figure 4.2: 3D mobility spectrum of neat GBL taken in negative ion mode

84

Figure 4.3: IMS analysis of solid GHB

GHB
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Figure 4.4: IMS analysis of GHB in urine

GHB
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Figure 4.5: IMS analysis of solid GHV

GHV
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Figure 4.6: IMS analysis of GHV in urine

GHV
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Figure 4.7: 3D mobility spectrum of the GHV headspace analysis

GHV peak is indicated by the arrow, a barely discernible response.
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Chapter 5: Application of Gas Chromatography-Mass
Spectrometry to the Analysis of GHB and GHV in Beverages [55]
5.1.0: Introduction
This researched was published in the Journal of Forensic Science in 2007 [55]. Research
presented here sought a confirmatory technique for identification of GHB and GHV to complete
a comprehensive suite of techniques available for forensic chemists in drug analysis.
SWGDRUG classifies both gas chromatography and mass spectrometry as category A
techniques. Therefore when information from both instruments is used, gas chromatographymass spectrometry (GC-MS) is considered a confirmatory technique. GC-MS is readily
available to most forensic laboratories and is an effective method for the detection of GHB and
GBL in aqueous and toxicological solutions [56-59]. Therefore, a GC-MS method has been
developed for detection of GHB and GHV in a variety of beverages. As previously noted, GHB
and GHV have been implicated as agents of DFSA via surreptitious use in beverages. An
average dose in a beverage has been anecdotally reported to be between 3 – 8g in a 12oz (355ml)
serving, correlating to between 0.8% - 2.3% w/v (8400 - 22500 ppm) [60].
Sample preparation for GC analysis of GHB and GHV includes BSTFA-TMCS
derivatization to counter thermal degradation of the small molecule. Unfortunately,
derivatization induces ring opening of the lactone [61-63] making this GC-MS method
insufficient for simultaneous detection of GHB and GBL. This study found that using a
surrogate spike improved the GC-MS method by providing a means of tracking analyte recovery.
Surrogate spikes are used in environmental analytical methods to measure analyte
recovery for individual samples. A surrogate compound is one that is chemically similar to the
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analyte and thus is expected to respond to analytical conditions similar to the analytes.
Surrogates must be compounds that are not expected to be found in samples themselves. These
criteria are the same as used to select an internal standard; the difference is in how the two
compound types (surrogates and internal standards) are integrated into the analysis and how the
resulting data are interpreted. An internal standard is used as the basis of a ratio of
concentrations and responses to generate a calibration curve. The surrogate is treated as an
analyte and the percent recovery of the surrogate, determined using an internal standard
calibration method, is used to gauge the recovery for an individual sample. A surrogate spike
provides an additional level of quality assurance and can identify intrinsically difficult matrices
within a sample batch. This capability is valuable in the context of GHB and related analyses
given the known difficulties associated with these samples and matrices [41, 54, 64]. When
supplemented by a surrogate spike, the present method yielded 97% analyte recovery from
beverages.

5.2.0: Experimental
5.2.1: Materials
Solutions of 99% GVL and GBL were obtained from Fluka (Ronkonkoma, NY) and solid
NaGHB was obtained from Sigma-Aldrich (St. Louis, MO). NaGHV was synthesized via the
hydrolysis of GVL with NaOH (Chapter 2). The GHV synthesis method was confirmed using IR
spectroscopy and H1NMR to elucidate the structure of the reaction product.
The internal standard was 1,5-pentanediol and the surrogate spike was 1,2-hexanediol;
both were obtained from Sigma-Aldrich (St. Louis, MO). Derivatizing agent was N, Obis(trimethylsilyl)triflouroacetamide (BSTFA) with trimethylchlorosilane (TMCS) obtained from
Supelco (Bellefonte, PA).
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5.2.2: Instrumentation
The GC-MS used in this study was an Agilent gas chromatograph model 6890 with mass
selective detector model 5973. The GC was operated in splitless injection mode with an
injection port temperature of 250°C. The carrier gas was helium and flow rate was maintained at
1.0 mL/min. An initial oven temperature of 50°C was held for 5 min. The temperature was then
ramped at a rate of 10°C/min to 100°C, held for 1 minute, followed by a temperature ramp of
40°C/min to a final temperature of 230°C. Total GC-MS analysis time was 9.25 minutes
including a 6 minute solvent delay. An HP-5 capillary column was employed (30m x 0.25mm
i.d. x 0.25μm film). Quadrupole mass spectrometry was employed for detection. The
quadrupole was scanned from 50 to 550 m/z. Quadrupole temperatures were maintained at
200ºC and the ion source was maintained at 250ºC. The mass spectrometer was tuned using
PFTBA.
5.2.3: Procedure
To create a calibration curve, standard solutions containing dissolved NaGHB and
NaGHV were made in deionized water and spiked with the internal standard 1,5-pentanediol
(PD) and the surrogate 1,2-hexanediol (HD). Nine replicate calibration curves were analyzed
and averaged.
All solutions, standards (for the calibration curve), and beverages (for the beverage study)
were prepared for GC-MS analysis by derivatization with BSTFA-TMCS. A stock solution of
200mg/mL GHB and GHV was prepared in deionized water. From the stock solutions, the
following standards were created by dilution with deionized water: 100, 75, 50, 25, 5, 1, 0.4, and
0.2mg/mL. 100μL of surrogate spike solution (50mg/mL 1,2HD) was added to 100μL of each
standard and the solution was diluted to 1mL with deionized water. Resulting concentrations
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were 10, 7.5, 5, 2.5, 0.5, 0.1, 0.04, and 0.02mg/mL. For each run, 1μL of internal standard
(5mg/mL 1,5PD) was added to 1μL of surrogate spiked standard and derivatization was induced
by addition of BSTFA. Resulting Concentrations were 100, 75, 50, 25, 5, 1, 0.4, and 0.2ppm
(µg/mL). Derivatized solutions were then capped, vortexed, and heated at 70°C for 15 minutes.
Derivatized sample was directly injected into the GC-MS. Quantitation was based on selected
ion monitoring; derivatized GHB was quantitated using the peak area of the ion at 233 m/z and
derivatized GHV was quantitated using the peak area of the ion at 157 m/z.
For the beverage study, a variety of beverages were used including: water, Tropicana®
cranberry juice cocktail with Barton® vodka (1.5oz vodka and 10.5oz cranberry juice), Coca
Cola®, Guinness Stout® beer, Coors Light® beer, and Willi Haag® Riesling (2003). All
beverages were obtained from local stores. 20mL of each beverage was spiked with
approximately 4g of NaGHB and NaGHV yielding stock beverages of approximately
200mg/mL. Final concentration of NaGHB and NaGHV was approximately 1ppm when
sampled (see Table 5.1 for concentrations). Three aliquots of each spiked beverage were
analyzed in triplicate.

5.3.0: Results
5.3.1: Validation of the GC-MS Method
Results of the GC-MS analysis of standard solutions are shown in Table 5.2 and Figures
5.1 and 5.2. Retention times were as follows: 1,5-Pentanediol (7.759min), GHB (7.791min), 1,2Hexanediol (7.902min), and GHV (7.938min) (See TIC, Figure 5.1). The limit of detection is
defined as the lowest analyte concentration which produces a signal-to-noise ratio of 3. For both
GHB and GHV the limit of detection was found to be 0.001ppm; which corresponds to an initial
beverage concentration of 1ppm.
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5.3.2: Beverage Study
Derivatization efficiencies of GHB and GHV were calculated by dividing the resulting
ion peak areas for derivatized analytes by the ion peak areas obtained during calibration and
were found to range from 88.5% to 100% and 92.9% to 100% respectively when the GC-MS
analytical procedure is used on beverages. Each beverage was sampled nine times. Figures 5.35.8 show typical total ion chromatograms (TIC) for derivatized GHB, derivatized GHV, internal
standard, and surrogate spike in water, Coors Light®, cranberry juice with vodka, Coca-Cola®,
Guinness Stout®, and Willi Haag® Riesling. Table 5.1 shows the results of the beverage
analysis. GHB, GHV, internal standard, and surrogate spike were detected in all beverages and
no interfering peaks were seen. The surrogate was added at a known concentration and has
similar molecular structure to the analytes of interest; thus it is useful for forensic beverage
analysis to monitor analyte recovery from inconsistent and complicated matrices. Average
recovery of the surrogate spike was 97%.

5.4.0: Conclusion
Commonly available in forensic laboratories, GC-MS has been shown to be an effective
method to detect and distinguish GHB and GHV in beverages. Beverages are complicated
matrices (colored with variable pH) and surreptitious doses of GHB are reported to be quite high
(8400 - 22500 ppm) [60]. This study used a BSTFA-TMCS derivatization scheme for sample
preparate which prevented thermal degradation of analytes and allowed for dilution to ranges
suitable for GC-MS analysis. Unfortunately, derivatization induces ring opening of the lactone
[59-63] making this GC-MS method insufficient for simultaneous detection of GHB and GBL.
The validated method was effective for detection of GHB, GHV, internal standard, and
surrogate spike in all beverages with no interfering peaks. The linear dynamic range was 0.01 –
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10 ppm which correlates to a beverage concentration of 10 – 10000 ppm. The limit of detection
was 0.001 ppm which correlates to 1 ppm in beverages. Sample preparation was effective on all
beverages producing derivatization efficiencies of 88.5% - 100%.
Due to the extensive sample preparation, a surrogate spike was used to measure analyte
recovery for individual samples. The surrogate was treated as an analyte and the percent
recovery of the surrogate, determined using an internal standard calibration method, was found
to be between 93% and 113% over all beverage samples with an average recovery of 97%.
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Table 5.1: Results of the beverage study by GC-MS
Beverage

NaGHB

NaGHV

Surrogate Spike

Actual

Measured

Actual

Measured

Actual

Measured

Cran & Vodka

0.96

0.85 + .04

1.29

1.23 + .05

0.98

0.93 + .01

Coors Light®

1.02

0.93 + .11

1.10

1.10 + .14

0.98

0.94 + .02

Coca Cola®

1.06

0.96 + .11

1.06

1.19 + .07

0.98

0.99 + .08

Guiness Stout®

1.01

0.92 + .04

1.01

0.98 + .05

0.98

0.94 + .02

Willi Haag®

0.96

0.97 + .03

1.12

1.04 + .04

0.98

0.94 + .01

0.98

1.00 + .07

0.93

0.96 + .04

0.98

0.98 + .03

Riesling
Water

All units are ppm (µg/mL). n = 9 trials.
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Table 5.2: Results of GC-MS calibration

LOD

Range

R2

Analyte

GC/MS

GHB

0.001 ppm

GHV

0.001 ppm

GHB

0.01 – 10 ppm

GHV

0.01 – 10 ppm

GHB

0.999

GHV

1.000
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Figure 5.1: GC calibration curve for GHB
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Figure 5.2: GC calibration curve for GHV
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Figure 5.3: TIC of analytes in water
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Chromatogram 5.3 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
deionized water.

100

Figure 5.4: TIC of analytes in Coors Light®
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Chromatogram 5.4 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
Coors Light®.
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Figure 5.5: TIC of analytes in cranberry juice with vodka
2500000

Abundance

2000000

1500000

abcd
1000000

500000

0
6

6.5

7

7.5

8

8.5

9

9.5

Retention Time (min)

Chromatogram 5.5 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
cranberry juice with vodka.
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Figure 5.6: TIC of analytes in Coca-Cola®
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Chromatogram 5.6 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
Coca-Cola®.
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Figure 5.7: TIC of analytes in Guinness Stout®
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Chromatogram 5.7 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
Guinness Stout®.
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Figure 5.8: TIC of analytes in Willi Haag® Riesling
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Chromatogram 5.8 shows (a) 1,5-pentanediol, (b) GHB, (c) GHV, and (d) 1,2-hexanediol in
Willi Haag® Riesling.

105

Figure 5.9: Mass spectrum of derivatized GHV
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Chapter 6: Inhibition of the Metabolism of GHB by Ethanol
6.1.0: Introduction
Forensic toxicologists and pathologists are regularly called on to evaluate the role and
magnitude of effects of ethanol and/or GHB in Drug-Facilitated Sexual Assaults (DFSA),
accidental overdoses, and homicides. Understanding the potential impact of ethanol on GHB
metabolism would be a valuable tool to facilitate understanding of the mechanism and role both
drugs may have played in a particular case or incident.
Ethanol ingestion may precede or facilitate delivery of GHB in cases of drug facilitated
sexual assault (DFSA) and is often detected in victims of this crime, either alone or in
combination with other drugs. Separate studies on reported victims of DFSA completed in 2000
and 2002 reported ethanol as present in 41% and 46% of studied cases, respectively [12,69].
This same study also cited GHB as an exogenous agent in 3% of DFSA cases. However, the
author cautioned that the number of cases resulting from GHB may actually be higher due the
molecule’s short half-life in the body [12].
As previously stated, the effects of administered GHB, as a CNS depressant, are thought
to be a function of its ability to mimic stimulation of the GABAA receptor due to its structural
homology with the endogenous GABA ligand, γ-aminobutryic acid (GABA) [30]. In the brain,
GHB is found endogenously at micromolar concentrations (human 11-25 μM, rat 0.4-4.6 μM)
[30]. At such endogenous levels, the concentration of GHB is insufficient to activate the GABA
receptor and normal physiological effects are likely due to activation of a separate, yet
unidentified, G protein-coupled presynaptic receptor [31]. GHB metabolism is theorized to
proceed via oxidation to succinyl semialdehyde (SSA), and subsequently to succinate (11) as
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shown in Figure 1.5. The metabolism of GHB may be mediated by three independent enzymes
(A) a cytosolic GHB dehydrogenase, (B) a mitochondrial transhydrogenase, and (C) fatty acid βoxidation.
Studies have attempted to model the effects of co-consumption on humans by using rats.
Such animal studies have shown that the coadministration of ethanol and GHB induces longer
sleeping time in rats than would be expected by the sum of sleeping time induced by the
individual compounds [36,38]. However, a mechanistic basis for such pharmacokinetic effects
of coadministration has not been suggested. One early study by McCabe et al. [36] focused on
the sleep time of rats following administration of GHB, GBL, and ethanol. The effects of
coadministration were found to be greater than additive for GBL/ethanol and GHB/ethanol
combinations. The results of McCabe’s study suggest that coadministration of GHB and ethanol
causes an increased duration of CNS depressant effects of one or both analytes. An increased
duration of effects is consistent with a common metabolic pathway, where the metabolism of one
analyte, presumably GHB, is hindered by the competitive presence of a second analyte, in this
case, ethanol. Sassenbroeck et al. [38] characterized coadministration of ethanol and GHB in
rats. They concluded, in agreement with previous studies, that the sleeping time of rats given
GHB and ethanol was significantly longer than the sum of sleeping times produced by individual
analytes. The increase in sleep time in this study was attributed to a pharmacodynamic
interaction between GHB and ethanol [38].
This study sought to understand the effects of ethanol on the metabolism of GHB in
humans. GHB is a CNS depressant that has been used as a recreational drug and an agent of
DFSA. Because of the structural homology between ethanol and the beta and gamma carbons of
GHB, ethanol, at concentrations consistent with recreational exposure (~ 0.1g/100ml), could
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provide significant competitive inhibition of the oxidation of GHB to succinyl semialdehyde
(SSA), with an effect on the pharmacokinetics of GHB. Inhibition of GHB metabolism would be
expected to exacerbate the effects of GHB producing an increase in area under the curve (AUC),
enhanced effects, and increased duration of action of GHB following ingestion with alcohol.

6.2.0: Experimental
6.2.1: Materials
All solutions were prepared using 18ΜΩ deionized water (E-pure system, Geneq Inc.,
Montreal, Quebec). Buffers were prepared using potassium phosphate (KH2PO4) (Riedel-de
Haen) and potassium hydroxide (KOH) (Fisher Scientific) or sodium phosphate (Riedel-de
Haen), sodium hydroxide (Fisher Scientific), and barbital (Sigma Aldrich). GHB and perchloric
acid were obtained from Sigma Aldrich. Succinic semialdehyde solution was obtained from
Fluka. Internal standard candidates included formic acid (EMD), glacial acetic acid (EM
Science), propionic acid (Mallinckrodt), malonic acid (Sigma Aldrich), benzoic acid (Fluka), and
hexanoic acid (Acros). All samples were filtered prior to analysis using sterile disposable
syringes obtained from BD Biosciences and filters obtained from Millipore (Millex hydrophobic
fluorophore PTFE).
Rat livers were obtained from Dr. Jason Huber of the Department of Pharmaceutical
Sciences at West Virginia University. Livers were prepared using a Potter-Elvehjem
homogenizer followed by ultra-centrifugation with the assistance of Dr. Kenneth Blemings of the
Division of Animal and Nutritional Sciences at West Virginia University.
6.2.2: Instrumentation
Initial work was done using a P/ACE MDQ capillary electropherograph with PDA
detector. The capillary featured the following dimensions: 366μm (o.d.) x 50μm (i.d.) x 20μm
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(coating) x 50cm (length to detection window). Every morning the instrument was flushed with
1.0M NaOH for 15 min and filtered deionized water for 10 min. This flush was repeated
between runs as needed. Prior to each injection, the instrument was flushed with 1.0M NaOH
for 3 min, filtered deionized water for 2 min, and run buffer (5mM Na2HPO4, 15mM barbital,
pH 12) for 2 min. Samples were injected at 1.0psi for 5 sec. Separation was facilitated at a
voltage of 30kV for 8 min at a constant temperature of 25°C. Detection was done at 238nm
(corresponding to the maximum absorbance of barbital). This method was adapted from
previously published methods for detection of GHB in biological fluids [65-67].
In later studies, spectroscopy was used to assay NADPH formation at 340nm. The
instrument used in this study was a Beckman Coulter DU 640, which was made available by Dr.
Blemings of the Animal and Veterinary Sciences Department of the Davis College of
Agriculture, Forestry, and Consumer Sciences. Cuvettes were obtained from VWR.
6.2.3: Procedure
Capillary Electrophoresis
Method Validation
Calibration was performed in triplicate, including sample blanks (buffers, water, and
internal standard) and zero blanks (buffers and water only) analyzed between trials. To evaluate
reproducibility, inter- and intraday precision were evaluated by analyzing 15 high quality control
standards at 125ppm and 15 low quality control standards at 75ppm over a period of three days.
QC standards were run with each metabolism batch and results were considered to be accurate if
the high and low QC standards (125 and 75ppm respectively) were within 20% of the expected
value.
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Sample Preparation
Physiological buffer was prepared using 5mM sodium phosphate adjusted to pH 7.67
with 1M sodium hydroxide. Run buffer was prepared using 5mM sodium phosphate and 15mM
barbiturate adjusted to pH 12 with 1M sodium hydroxide.
Calibration standards were created using stock solutions of GHB and internal standard
(hexanoic acid) at approximately 1000ppm in filtered deionized water. Samples for CE analysis
consisted of 20μL internal standard stock solution, 20μL physiological buffer (5mM Na2HPO4,
pH 7.67), sufficient GHB stock solution to reach target concentration (approximately 5μL –
30μL), and sufficient filtered deionized water to bring the final volume to 200μL. Samples were
vortexed and then diluted 1:1 in CE run buffer (5mM Na2HPO4, 15mM barbiturate, pH 12) and
revortexed prior to analysis.
Rat liver was diluted 1:2 (w/v) in 0.1M KH2PO4 buffer pH 7.6 for homogenization.
Homogenate was centrifuged at 12000 x g for 10min. Supernatant was collected and centrifuged
for 105000 x g for 1 hour. The supernatant cytosolic fraction was collected and stored at -80°C.
For metabolism, sample solutions were made similarly to calibration standards. A stock
solution of 750ppm NADP+ was prepared daily. Samples consisted of 20μL internal standard
stock solution, 20μL physiological buffer (5mM Na2HPO4, pH 7.67), 15μL cytosolic fraction,
20μL NADP+ stock solution, sufficient filtered deionized water to bring the final volume to
185μL, and sufficient GHB stock solution to reach target concentration (approximately 5μL –
30μL). Samples were vortexed then incubated at 35°C for 3 minutes, timed from the addition of
GHB. Metabolism was stopped via addition of 15μL perchloric acid. Samples were diluted 1:1
in CE run buffer (5mM Na2HPO4, 15mM barbital, pH 12) and revortexed prior to analysis.

111

Spectroscopy
For metabolism, a stock solution of 0.025M NADP+ was prepared daily. Stock solutions
of GHB and ethanol were prepared at 0.1M. Physiological buffer was prepared as 0.8M KH2PO4
at pH 7.6. Harvested rat livers were diluted 1:2 (w/v) in 0.08M KH2PO4 buffer pH 7.6 for
Potter-Elvehjem homogenization. Homogenate was centrifuged at 105000 x g for 1 hour. The
supernatant cytosolic fraction was collected and stored at -80°C.
To find the optimum time of metabolism, one large metabolism solution was mixed and
aliquots were removed over time. The metabolism solution consisted of 0.0185g NADP+ (final
concentration 0.0025M), 5mL cytosolic fraction, 1mL physiological buffer, 1mL GHB stock
(final concentration 0.01M), and 3mL filtered deionized water to bring the final volume to
10mL. 1mL aliquots were removed at intervals of 3, 10, 15, 30, and 45 minutes. Samples were
incubated at 37°C and timed from the addition of GHB. Metabolism was stopped via addition of
100μL 60% perchloric acid to each aliquot. Solution was then centrifuged at 5000 rpm for 5
minutes to remove precipitate. NADPH was assayed at 340nm.
Samples consisted of 500μL cytosolic fraction, 100μL physiological buffer, 100μL
NADP+ stock solution (for a final concentration of 0.0025M), 100μL ethanol stock solution
(inhibition study samples only), sufficient filtered deionized water to bring the final volume to
1mL, and sufficient GHB stock solution to reach target concentration (0.01M). A blank sample
was run with every trial containing all the previous listed contents except GHB. Samples were
incubated at 37°C for 3 minutes, timed from the addition of GHB. Metabolism was stopped via
addition of 100μL 60% perchloric acid. Solution was centrifuged at 5000 rpm for 5 minutes to
remove precipitate. NADPH was assayed at 340nm.
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6.3.0: Results
Capillary Electrophoresis
Several compounds were tested for suitability as an internal standard. The internal
standard requirements were structural similarity to GHB (a small carboxylic acid), resistance to
metabolism, and simultaneous detection with GHB and SSA (a metabolite of GHB). Formic
acid, glacial acetic acid, propionic acid, and malonic acid were found to be unresponsive to CE
with indirect UV detection. The resulting peak for benzoic acid was obscured by succinic
semialdehyde (the expected metabolite of GHB). Hexanoic acid was found to be a suitable
internal standard for analysis; featuring detection using CE indirect with UV analysis, no
interference with detection of GHB or SSA, and resistance to metabolism (Figure 6.1).
The linear dynamic range for GHB was found to be 25ppm to 150ppm with a
corresponding R2 value of 0.9987. The method showed excellent inter- and intrarun precision,
which was evaluated by analysis of 15 HQC (125ppm) and 15 LQC (75ppm) standards over
three consecutive days (n=5/day). Interrun precision experiments provided a %RSD of 5.15%
and 6.19% for HQC and LQC standards, respectively. Intrarun precision experiments provided
an average %RSD of 4.81% and 5.39% for HQC and LQC standards, respectively.
Spectroscopy
To find the optimum time of metabolism, one 10mL metabolism solution was prepared
and 1mL aliquots were removed at 3, 10, 15, 30, and 45 minutes. The results of this study are
shown as Figure 6.2. The rate of appearance of product (NADPH) appears to saturate around 20
minutes, therefore 10 minutes was selected for subsequent metabolism reactions.
When evaluating metabolism, it is expected that a graph of rate versus concentration of
substrate will show a similar pattern to Figure 1.8. However, Figure 6.3 shows data obtained
113

from metabolism reactions. As can be seen, the data is not appropriate for Lineweaver-Burke
transformation to determine both Km and KI. However, one observation can be made supporting
the hypothesis suggested here: when the metabolism is carried out in the presence of ethanol, less
NADPH is formed resulting in lower absorbance at 340nm.
In addition, other parameters were tested in the pursuit of data amenable to LineweaverBurke transformation. The amount of enzyme used in the metabolism was varied from 100µL in
1mL to 500µL in 1mL however no change in absorbance was seen for enzyme amounts lower
than 500µL/mL. The metabolism was also tested at room temperature and no production of
NADPH was seen. Incubation at 37°C during the course of the metabolism is necessary for data
collection. The time between centrifugation to remove precipitate following addition of
perchloric acid was timed and minimized due to a slow but steady increase in absorbance noted
in all samples (including blanks) when left at room temperature following centrifugation. As
perchloric acid was used to stop the reaction, the amount was varied to combat this post analysis
absorption increase; however, when the amount of perchloric acid used to stop the reaction was
increased, an increase in absorbance was seen in all samples (including blank).

6.4.0: Conclusion
Because of the structural homology between ethanol and the beta and gamma carbons of
GHB, ethanol, at concentrations consistent with recreational exposure (~ 0.1g/100ml), could
provide significant competitive inhibition of the oxidation of GHB to succinyl semialdehyde
(SSA), with an effect on the pharmacokinetics of GHB. Inhibition of GHB metabolism would be
expected to exacerbate the effects of GHB producing an increase in area under the curve (AUC),
enhanced effects, and increased duration of action of GHB following ingestion with alcohol.
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Although capillary electrophoresis was an effective method for separating and detecting
both GHB and its metabolite, succinic semialdehyde (SSA); it was ineffective for detection of
SSA at concentrations produced by metabolism. No production of SSA was seen using this
method.
Spectroscopy is an effective method to measure production of NADPH from the
metabolism of GHB. When both GHB and ethanol are present in cellular digests containing
cytosolic GHB dehydrogenase, less NADPH is produced; tentatively supporting a hypothesis
that ethanol may inhibit the metabolism of GHB. However, this study failed to generate data
sufficient for Lineweaver-Burke transformation necessary to calculate a KI. A non-linear
response in product formation was seen when the concentration of GHB was increased. In
investigating the phenomenom, several potential sources of error were checked. First the
instrument was considered suspect; however, the instrument was successfully used during the
course of this experimental work by members of Dr. Blemings research group. In addition, all
cuvettes were used directly from manufacturer’s packing and were disposed of after single use as
washing caused a significant increase in absorbance. Buffer, enzyme, and analyte solutions
(GHB and ethanol) were made up monthly, while NADPH solutions were made fresh daily.
Using freshly prepared buffer, enzyme, and analyte solutions yielded no obvious changes in the
linearity of results. Indeed, the reported studies of GHB metabolism yielding calculations of the
Michaelis-Menten constant do not specify how often solutions were refreshed and also neglect to
mention the amount of liver homogenate used in metabolism reactions.
Further research should seek to investigate of mitochondrial uptake of GHB and ethanol.
If successful, the effects of ethanol on the metabolism of GHB by the mitochondrial GHB
transhydrogenase should be studied.
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Figure 6.1: Results of CE analysis.

The blue electropherogram shows a metabolism mixture where the only peaks seen are GHB and hexanoic acid (IS). No succinic
semialdehyde (the metabolism product of GHB) is seen. The green electropherogram is cytosolic fraction with no GHB or IS added.
The red electropherogram is a 125ppm solution of GHB and IS in buffer.
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Figure 6.2: Timed metabolism showing absorbance of NADPH.
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Figure 6.3: Metabolism of GHB alone and in the presence of ethanol.
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Summary
GHB and GHV are suspected agents of DFSA. This research sought to improve
detection methods for both drugs for a range of instrumentation. Focusing on instruments and
methods commonly available to forensic chemists, screening and confirmatory analyses were
optimized to detect and distinguish both analytes. Lastly, the metabolism of GHB in the
presence of alcohol was studied to improve understanding of the effects of coadministration.
Chapter 2 discussed the synthesis of GHV via base hydrolysis of GVL. The results of the
synthesis were confirmed using previously proven IR spectroscopy and H1NMR spectrometry.
The GHV produced was used for all future instrumental studies.
Chapter 3 evaluated microcrystal testing for efficacy in detecting GHB and GHV in
beverages (lactones were unsuitable for crystal formation). The microcrystal test was confirmed
to be sensitive to 0.01% w/v GHB and GHV in beverages while distinguishing both analytes
based on crystal shape. GHB and GHV crystals are also distinguishable via angle measurement
to improve objectivity of the analysis.
Chapter 4 evaluated a second screening test in the form of IMS. IMS has recently found
popularity in the field of forensic chemistry via its use by the Department of Homeland Security
for explosive detection in airports and chemical testing of warfare agents in the field. IMS was
found to detect and respond to GHB, GBL, BD, GHV, and GVL at concentrations of 3ppm in
water and urine. This makes IMS a viable screening technique for neat analyte, aqueous
solutions, and biological solutions (urine was tested, saliva may be feasible).
Chapter 5 showed the validation of a confirmatory method, GC-MS, for the separation
and detection of GHB and GHV (lactones were found to undergo ring opening upon
derivatization). This method was shown to be effective for analysis of suspect beverages. The
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use of a surrogate spike was a welcome addition for its use in identifying intrinsically difficult
sampling matrices.
Chapter 6 investigated the metabolism of GHB in the presence of alcohol. For DFSA, it
is expected that drug will be delivered surreptitiously in alcoholic beverages. Decreased
production of NADPH from the metabolism of GHB in the presence of ethanol supports the
hypothesis that ethanol inhibits the metabolism of GHB.
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Future Work
GHB and GHV remain drugs of concern both to controlled substance analysts and
toxicologists. Several projects could build on the research discussed here. For example, the
development of improved extraction techniques would enable crystal analysis of beverages not
amenable to crystal formation with silver (including wine and juice). In addition, XRD is a
useful tool that could be used to confirm the specificity of a variety of crystal tests making them
an effective screening tool for many controlled substances. Since the publication of this
research, several researchers have expressed their interest in using XRD on a broad range of
drugs and microcrystal reagents.
In IMS analysis, several peaks were found to be formed by all analytes (GHB, GBL,
GHV, and GVL). The authors hypothesized that these peaks could be the result of dimer or
trimer formation, however the development of an IMS method coupled to a detector capable of
structure determination could confirm the structures seen. These peaks could be found to be
useful for detection of GHB, GBL, GHV, and GVL.
Future work on both screening methods could include a demonstration of efficacy for
examination of nonconventional biological solutions (such as saliva and breath). To date, GCMS, HPLC with fluorescent detection, and H1NMR have been used to determine GHB
concentrations in saliva. The development of a screening test would enable toxicological
laboratories to quickly test samples before dedicating time and resources to such confirmatory
testing of submitted samples. Meanwhile no references have been found for detection of GHB in
breath.
The metabolism of GHB is well understood but the cause of enhanced effects from
coadministration with alcohol is not. Future work in this field could include investigation of the
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ability of GHB and ethanol to cross the mitochondrial membrane. Once mitochondrial uptake is
established, GHB transhydrogenase should be investigated for interference by ethanol.
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